Alert archive
Every CMS and MAC reimbursement policy change CLV Intelligence tracks — 1,645 alerts across 47 specialty areas, newest first. Each alert links to its affected CPT/HCPCS/ICD-10 codes, effective date, and a plain-English summary of what changed.
Multi-specialty371
- FDA Approval: NDA 220106 — Type 1 - New Molecular Entity2026-09-03
- FDA Approval: NDA 221443 — Type 4 - New Combination2026-09-03
- CMS Transmittal R13943CP: October 2026 Quarterly Update to Healthcare Common Procedure Coding System (HCPCS) Codes Used…2026-09-02
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-09-02
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-09-01
- CMS Transmittal R13934OTN: Health Insurance Portability and Accountability Act (HIPAA) Electronic Data Interchange(EDI)…2026-08-28
- LCD L39051: Cosmetic and Reconstructive Surgery — WPS2026-08-27
- CMS Transmittal R13904CP: Updates to Chapter One of the Medicare Claims Processing Manual (Publication (Pub.) 100-04) to…2026-08-27
- CMS Transmittal R13938CP: Instructions for Downloading the Healthcare Common Procedure Coding System (HCPCS) Files for the…2026-08-27
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-08-27
- FDA Approval: TAKHZYRO (LANADELUMAB-FLYO) — Type 1 - New Molecular Entity2026-08-26
- FDA Approval: BLA 761508 — Type 1 - New Molecular Entity2026-08-22
- CMS Transmittal R13881CP: October 2026 Quarterly Update to Healthcare Common Procedure Coding System (HCPCS) Codes Used…2026-08-22
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-08-21
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-08-21
- FDA Approval: NDA 218524 — Type 5 - New Formulation or New Manufacturer2026-08-20
- FDA Approval: LIDOCAINE (LIDOCAINE HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer2026-08-20
- LCD L40326: Allergy Diagnostic Testing — CGS2026-08-20
- CMS Transmittal R13933OTN: Fiscal Intermediary Shared System (FISS) - Modify the Expert Claims Processing System (ECPS) to…2026-08-20
- FDA Approval: ZUBSOLV (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer2026-08-19
- FDA Approval: SUBOXONE (BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE) — Type 4 - New Combination2026-08-19
- CMS Transmittal R13910OTN: International Classification of Diseases, 10th Revision (ICD-10) and Other Coding Revisions to…2026-08-15
- CMS Transmittal R13923OTN: International Classification of Diseases, 10th Revision (ICD-10) and Other Coding Revisions to…2026-08-15
- LCD L40324: Allergy Diagnostic Testing — Noridian2026-08-13
- LCD L40341: Allergy Diagnostic Testing — WPS2026-08-13
- LCD L40328: Allergy Diagnostic Testing — Palmetto GBA2026-08-13
- LCD L40330: Allergy Diagnostic Testing — Wellpoint Federal2026-08-13
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-08-13
- Federal Register Notice: Medicare Program; Alternative Payment Model (APM) Incentive Payment Advisory for Clinicians-Request for Current Billing Information for Qualifying APM Participants2026-08-13
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-08-12
- Federal Register Notice: Medicare Program; Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway2026-08-11
- CMS Transmittal R13903OTN: International Classification of Diseases, 10th Revision (ICD-10) and Other Coding Revisions to…2026-08-08
- CMS Transmittal R13906OTN: International Classification of Diseases, 10th Revision (ICD-10) and Other Coding Revisions to…2026-08-08
- Federal Register Notice: Privacy Act of 1974; Matching Program2026-08-05
- FDA Approval: CELLCEPT (MYCOPHENOLATE MOFETIL) — Type 3 - New Dosage Form2026-08-04
- FDA Approval: CELLCEPT (MYCOPHENOLATE MOFETIL) — Type 1 - New Molecular Entity2026-08-04
- FDA Approval: NDA 220381 — Type 2 - New Active Ingredient2026-08-04
- Federal Register Notice: Healthcare Advisory Committee (HAC); Announcement of the HAC Meetings for Fiscal Year 2026-20272026-08-04
- FDA Approval: MYFORTIC (MYCOPHENOLIC ACID) — Type 2 - New Active Ingredient2026-08-01
- FDA Approval: CELLCEPT (MYCOPHENOLATE MOFETIL) — Type 3 - New Dosage Form2026-08-01
- FDA Approval: CELLCEPT (MYCOPHENOLATE MOFETIL HYDROCHLORIDE) — Type 3 - New Dosage Form2026-08-01
- FDA Approval: QLONILIK (CLONIDINE HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer2026-08-01
- FDA Approval: MYHIBBIN (MYCOPHENOLATE MOFETIL) — Type 5 - New Formulation or New Manufacturer2026-08-01
- CMS Transmittal R13890PI: Revisions to Chapter 12 (The Comprehensive Error Rate Testing (CERT) Program) and Exhibit 46 in…2026-07-31
- CMS Transmittal R13891FM: Update to the Internet Only Manual (IOM) Publication (Pub.) 100-06 Chapter 8, Contractor…2026-07-31
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-07-31
- FDA Approval: ANTISEPTIC SKIN CLEANSER (CHLORHEXIDINE GLUCONATE) — Type 3 - New Dosage Form2026-07-30
- CMS Transmittal R13888OTN: Send 'Reason for Denial' Value in Prior Authorization Data to the Integrated Data Repository…2026-07-30
- Federal Register Final Rule: Medicare Program; Updates to the Master List of Items Potentially Subject to Face-to-Face Encounter and Written Order Prior to Delivery and/or Prior Authorization Requirements; Updates to the Required Face-to-Face Encounter and Written Order Prior to Delivery List; and Updates to the Required Prior Authorization List2026-07-30
- FDA Approval: FOAMING HAND WASH (CHLORHEXIDINE GLUCONATE) — Type 3 - New Dosage Form2026-07-29
- Federal Register Notice: Privacy Act of 1974; Matching Program2026-07-29
- Federal Register Notice: Medicare and Medicaid Programs; Quarterly Listing of Program Issuances-April Through June 20262026-07-25
- CMS Transmittal R13882OTN: Modify the Application Logic to Conditionally Retain the Medicare Carrier System (MCS) Medicare…2026-07-24
- CMS Transmittal R13879PI: Updates to Chapters 4 and Exhibit 16 in Publication (Pub.) 100-08, Including Updates to the…2026-07-24
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-07-24
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-07-24
- LCD L33614: Debridement Services — Wellpoint Federal2026-07-23
- LCD L33632: Psychiatry and Psychology Services — Wellpoint Federal2026-07-23
- LCD L33626: Psychiatric Partial Hospitalization Programs — Wellpoint Federal2026-07-23
- LCD L38937: Platelet Rich Plasma — Wellpoint Federal2026-07-23
- LCD L33616: Osteopathic Manipulative Treatment — Wellpoint Federal2026-07-23
- LCD L33580: Speech-Language Pathology — Wellpoint Federal2026-07-23
- LCD L33394: Drugs and Biologicals, Coverage of, for Label and Off-Label Uses — Wellpoint Federal2026-07-23
- Federal Register Notice: Notice of Public Data Asset Release Under the Open, Public, Electronic, and Necessary (OPEN) Government Data Act2026-07-23
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-07-21
- Federal Register Final Rule: Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program; Correction2026-07-21
- FDA Approval: ROCURONIUM (ROCURONIUM BROMIDE) — Type 5 - New Formulation or New Manufacturer2026-07-18
- Federal Register Notice: Medicare Program; Inflation Reduction Act of 2022 (IRA) Medicare Drug Price Negotiation Program Draft Guidance; Comment Request2026-07-18
- CMS Transmittal R13859CP: Influenza Vaccine Payment Allowances - Annual Update for 2026-2027 Season2026-07-17
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-07-17
- Federal Register Proposed Rule: Request for Information; Clinical Laboratory Improvement Amendments of 1988 (CLIA) Regulations2026-07-16
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-07-16
- FDA Approval: SODIUM BICARBONATE (SODIUM BICARBONATE) — Type 5 - New Formulation or New Manufacturer2026-07-15
- FDA Approval: TUXARIN (CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE) — Type 4 - New Combination2026-07-15
- CMS Transmittal R13869FM: Notice of New Interest Rate for Medicare Overpayments and Underpayments -4th Quarter…2026-07-15
- CMS Transmittal R13867CP: File Conversions Related to the Spanish Translation of the Healthcare Common Procedure Coding…2026-07-14
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-07-14
- FDA Approval: RYALTRIS (OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE) — Type 4 - New Combination2026-07-11
- CMS Transmittal R13856MSP: ECRS Update for Prescription Drug Inquiries (PDIs) to Prevent the Creation of Records with…2026-07-11
- CMS Transmittal R13865OTN: Health Insurance Portability and Accountability Act (HIPAA) Electronic Data Interchange(EDI…2026-07-11
- CMS Transmittal R13717PI: Incorporation of Recent Provider Enrollment Regulatory Changes into Chapter 10 of CMS…2026-07-10
- Federal Register Notice: Secretarial Comments on the Consensus-Based Entity's (CBE) (Battelle Memorial Institute) 2025 Activities: Report to Congress and the Secretary of the Department of Health and Human Services2026-07-10
- FDA Approval: ZYRTEC-D (CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE) — Type 4 - New Combination2026-07-08
- FDA Approval: ZYRTEC ALLERGY (CETIRIZINE HYDROCHLORIDE) — Type 3 - New Dosage Form2026-07-08
- Federal Register Notice: Privacy Act of 1974; Matching Program2026-07-03
- Federal Register Proposed Rule: Calendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Policies2026-07-03
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-07-03
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-07-02
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-07-02
- CMS Transmittal R13830CP: File Conversions Related to the Spanish Translation of the Healthcare Common Procedure Coding…2026-07-01
- CMS Transmittal R13829CP: Quarterly Update to the National Correct Coding Initiative (NCCI) Procedure-to-Procedure (PTP)…2026-06-30
- CMS Transmittal R13831CP: October 2026 Quarterly Average Sales Price (ASP) Medicare Part B Drug Pricing Files and…2026-06-30
- Federal Register Notice: Privacy Act of 1974; Matching Program2026-06-30
- FDA Approval: ADRENALIN (EPINEPHRINE) — Type 7 - Drug Already Marketed without Approved NDA2026-06-27
- FDA Approval: TRODELVY (SACITUZUMAB GOVITECAN) — Type 1 - New Molecular Entity2026-06-27
- FDA Approval: IBRANCE (PALBOCICLIB) — Type 3 - New Dosage Form2026-06-27
- FDA Approval: IBRANCE (PALBOCICLIB) — Type 1 - New Molecular Entity2026-06-27
- FDA Approval: TRYNGOLZA (OLEZARSEN SODIUM) — Type 1 - New Molecular Entity2026-06-27
- FDA Approval: SPRAVATO (ESKETAMINE HYDROCHLORIDE) — Type 2 - New Active Ingredient2026-06-27
- CMS Transmittal R244SOMA: Revisions to State Operations Manual (SOM), Chapter 72026-06-27
- Federal Register Final Rule: Medicaid Program; Community Engagement Requirement for Certain Individuals2026-06-27
- FDA Approval: TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE (TRAMADOL HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer2026-06-26
- FDA Approval: BUTRANS (BUPRENORPHINE) — Type 3 - New Dosage Form2026-06-26
- FDA Approval: COPAXONE (GLATIRAMER ACETATE) — Type 1 - New Molecular Entity2026-06-26
- FDA Approval: PROLIA (DENOSUMAB) — Type 1 - New Molecular Entity2026-06-26
- CMS Transmittal R13842CP: Quarterly Update for the Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS…2026-06-26
- CMS Transmittal R13839OTN: Implementation of The Technical Consolidation of the Electronic Data Interchange(TCEDI) as…2026-06-26
- Federal Register Proposed Rule: Medicare Program; CY 2027 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Acute Kidney Injury Dialysis (AKI) Payment, and ESRD Quality Incentive Program2026-06-26
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-26
- CMS Transmittal R13838CP: Quarterly Update to the Medicare Physician Fee Schedule Database (MPFSDB) - July2026 Update…2026-06-24
- CMS Transmittal R13804DEMO: Update to GUIDE Model Appendices for July 20262026-06-23
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-18
- Federal Register Proposed Rule: Request for Information (RFI): Pharmacy Benefit Manager Compensation and Data Collection2026-06-18
- FDA Approval: DEXTROSE (DEXTROSE MONOHYDRATE) — Type 5 - New Formulation or New Manufacturer2026-06-17
- FDA Approval: DEXTROSE (DEXTROSE MONOHYDRATE) — Type 5 - New Formulation or New Manufacturer2026-06-17
- CMS Transmittal R13833MSP: Creating Additional Medicare Secondary Payer (MSP) Error Codes to Better Identify Incoming MSP…2026-06-17
- CMS Transmittal R13792CP: October 2026 (2027 File) Update of the International Classification of Diseases, Tenth Revision…2026-06-16
- CMS Transmittal R13701CP: Update to Several Sections of the Internet-Only Manual (IOM) Publication (Pub.) 100-04,…2026-06-16
- Federal Register Proposed Rule: Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program2026-06-16
- Federal Register Final Rule: Medicare Program; Strengthening Oversight of Accrediting Organizations (AOs) and Preventing AO Conflicts of Interest, and Related Provisions2026-06-16
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-16
- CMS Transmittal R243SOMA: Revisions to State Operations Manual (SOM), Chapter 52026-06-13
- CMS Transmittal R13785FM: The Fiscal Intermediary Shared System (FISS) Submission of Copybook Files to the Provider…2026-06-13
- CMS Transmittal R13825FM: Updates to the Internet Only Manual, Publication 100-06, Chapter 3, Overpayments, Section 140-…2026-06-12
- CMS Transmittal R13826CP: Medicare Beneficiary Date of Death - Manual Update2026-06-12
- Federal Register Notice: Statement of Organization, Functions, and Delegations of Authority2026-06-11
- CMS Transmittal R13821PI: Updates of Chapters 3, 4, and Exhibits in Publication (Pub.) 100-08, Including Updates to the…2026-06-10
- Federal Register Notice: Announcement of the Approval of COLA as an Accreditation Organization for the Specialty of Histocompatibility Under the Clinical Laboratory Improvement Amendments of 19882026-06-10
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-10
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-10
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-10
- FDA Approval: CHILDRENS ALLEGRA ALLERGY (FEXOFENADINE HYDROCHLORIDE) — Type 3 - New Dosage Form2026-06-09
- FDA Approval: AFINITOR DISPERZ (EVEROLIMUS) — Type 3 - New Dosage Form2026-06-06
- FDA Approval: OZEMPIC (SEMAGLUTIDE) — Type 1 - New Molecular Entity2026-06-06
- FDA Approval: AFINITOR (EVEROLIMUS) — Type 1 - New Molecular Entity2026-06-06
- FDA Approval: SAXENDA (LIRAGLUTIDE) — Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated2026-06-06
- FDA Approval: TIOCYSTIN (TIOPRONIN) — Type 5 - New Formulation or New Manufacturer2026-06-06
- FDA Approval: FUROSEMIDE (FUROSEMIDE) — Type 5 - New Formulation or New Manufacturer2026-06-06
- FDA Approval: BRENZAVVY (BEXAGLIFLOZIN) — Type 1 - New Molecular Entity2026-06-06
- FDA Approval: FARXIGA (DAPAGLIFLOZIN) — Type 1 - New Molecular Entity2026-06-06
- FDA Approval: STEGLUJAN (ERTUGLIFLOZIN AND SITAGLIPTIN) — Type 4 - New Combination2026-06-06
- FDA Approval: STEGLATRO (ERTUGLIFLOZIN) — Type 1 - New Molecular Entity2026-06-06
- FDA Approval: QTERN (DAPAGLIFLOZIN) — Type 4 - New Combination2026-06-06
- FDA Approval: INVOKANA (CANAGLIFLOZIN) — Type 1 - New Molecular Entity2026-06-06
- CMS Transmittal R13551CP: Updates to the Internet Only Manual (IOM) Publication …2026-06-06
- CMS Transmittal R13553CP: National Fee Schedule for Vaccine Administration Quarterly Update - January 20262026-06-06
- CMS Transmittal R13556CP: Quarterly Update to Home Health (HH) Grouper2026-06-06
- CMS Transmittal R13545CP: Quarterly Update to the National Correct Coding Initiative (NCCI) Procedure-to-Procedure (PTP)…2026-06-06
- CMS Transmittal R13538CP: Cardiac Contractility Modulation (CCM) for Heart Failure (HF)2026-06-06
- CMS Transmittal R13538NCD: Cardiac Contractility Modulation (CCM) for Heart Failure (HF)2026-06-06
- CMS Transmittal R13519CP: Calendar Year 2026 Update for Durable Medical Equipment, Prosthetics, Orthotics and Supplies (…2026-06-06
- CMS Transmittal R13532CP: April 2026 Quarterly Average Sales Price (ASP) Medicare Part B Drug Pricing Files and Revisions…2026-06-06
- CMS Transmittal R13536CP: January 2026 Annual Rural Emergency Hospital (REH) Monthly Facility Payment Amount2026-06-06
- CMS Transmittal R13560OTN: Editing for Hospital Services Provided to Hospice Enrollees2026-06-06
- CMS Transmittal R13555OTN: Editing for Duplicate Processing for Practitioner Professional…2026-06-06
- CMS Transmittal R13460CP: Update to the Internet Only Manual (IOM) for Inpatient Billing of Chimeric Antigen Receptor (CAR…2026-06-06
- CMS Transmittal R13508CP: Implementation CR - Send Transplant Program Hospital Type and the New Organ Types to the Fiscal…2026-06-06
- CMS Transmittal R13494MPI: Updates of Chapters 1-5 in Publication (Pub.) 100-15, Including Updates to the Guidance…2026-06-06
- CMS Transmittal R13485PI: Updates of Chapter 4 in Publication (Pub.) 100-08, Including Updates to the Recovery Audit…2026-06-06
- CMS Transmittal R13478CP: File Conversions Related to the Spanish Translation of the Healthcare Common Procedure Coding…2026-06-06
- CMS Transmittal R13565DEMO: Implementation of Wasteful and Inappropriate Service Reduction (WISeR) Model Prior Authorization…2026-06-06
- CMS Transmittal R13510FM: Updates to Internet Only Manual, Publication 100-06, Chapter 4, Section 70.16 (Debt Close-Out)…2026-06-06
- CMS Transmittal R13561FM: Chapter 3 Sections 170-190 - General Overpayment Provisions - Update of Citations and…2026-06-06
- CMS Transmittal R13564OTN: Extensions of Certain Temporary Changes to the Low-Volume Hospital Payment Adjustment and the…2026-06-06
- CMS Transmittal R13562CP: April 2026 Update to the Medicare Severity – Diagnosis…2026-06-06
- CMS Transmittal R13566DEMO: Implementation of Wasteful and Inappropriate Service Reduction (WISeR) Model Prior Authorization…2026-06-06
- CMS Transmittal R13516BP: Implementation of Changes in the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS…2026-06-06
- CMS Transmittal R13569OTN: Integrated Data Repository (IDR) Daily Snapshot File2026-06-06
- CMS Transmittal R13570DEMO: Implementation of Wasteful and Inappropriate Service Reduction (WISeR) Model Prior Authorization…2026-06-06
- CMS Transmittal R13816OTN: Health Insurance Portability and Accountability Act (HIPAA) Electronic Data Interchange(EDI…2026-06-06
- CMS Transmittal R13818OTN: Implementation of Editing for Programs of All-Inclusive Care for the Elderly (PACE) Inpatient…2026-06-06
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model; Correction2026-06-05
- Federal Register Final Rule: Medicare Program; Updates to the Master List of Items Potentially Subject to Face to Face Encounter and Written Order Prior to Delivery and/or Prior Authorization Requirements; Updates to the Required Face-to-Face Encounter and Written Order Prior to Delivery List; and Updates to the Required Prior Authorization List2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Final Rule: Medicare Program; Updates to the Master List of Items Potentially Subject to Face-to-Face Encounter and Written Order Prior To Delivery and/or Prior Authorization Requirements; Updates to the Required Face-to-Face and Written Order Prior To Delivery List; and Updates to the Required Prior Authorization List2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Medicare Program; Medicare Part B Monthly Actuarial Rates, Premium Rates, and Annual Deductible Beginning January 1, 20242026-06-05
- Federal Register Proposed Rule: Federal Independent Dispute Resolution (IDR) Process Administrative Fee and Certified IDR Entity Fee Ranges2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of Nationwide Temporary Moratoria on Enrollment of Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Supplier Medical Supply Companies2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Medicare Program; Medicare Part B Monthly Actuarial Rates, Premium Rates, and Annual Deductible Beginning January 1, 20262026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model2026-06-05
- Federal Register Final Rule: Medicare Program: Mitigating the Impact of Significant, Anomalous, and Highly Suspect Billing Activity on Medicare Shared Savings Program Financial Calculations in Calendar Year 20232026-06-05
- Federal Register Proposed Rule: Medicare Program: Mitigating the Impact of Significant, Anomalous, and Highly Suspect Billing Activity on Medicare Shared Savings Program Financial Calculations in Calendar Year 20232026-06-05
- Federal Register Final Rule: Medicare Program; Medicare Prescription Drug Benefit Program; Health Information Technology Standards and Implementation Specifications2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Medicare Program; Transitional Coverage for Emerging Technologies2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs; Organ Procurement Organizations Conditions for Coverage: Revisions to the Conditions for Coverage2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs; Hospital Condition of Participation: Prohibiting Sex-Rejecting Procedures for Children2026-06-05
- Federal Register Proposed Rule: Medicaid Program; Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children2026-06-05
- Federal Register Proposed Rule: Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Medicare and Medicaid Programs; Quarterly Listing of Program Issuances-January Through March 20252026-06-05
- Federal Register Notice: Request for Information; Health Technology Ecosystem2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Medicare and Medicaid Programs; Quarterly Listing of Program Issuances-October Through December 20242026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Proposed Rule: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2026; and Basic Health Program2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Medicare Program; Transitional Coverage for Emerging Technologies2026-06-05
- Federal Register Final Rule: 21st Century Cures Act: Establishment of Disincentives for Health Care Providers That Have Committed Information Blocking2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Final Rule: Medicaid Program; Ensuring Access to Medicaid Services2026-06-05
- Federal Register Final Rule: Nondiscrimination in Health Programs and Activities2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Proposed LCD DL40062: MolDX: Molecular Testing for Solid Organ Allograft Rejection — Noridian2026-06-05
- Federal Register Final Rule: Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2025; Updating Section 1332 Waiver Public Notice Procedures; Medicaid; Consumer Operated and Oriented Plan (CO-OP) Program; and Basic Health Program2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Medicare and Medicaid Programs; Quarterly Listing of Program Issuances-October Through December 20232026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Proposed Rule: Federal Independent Dispute Resolution Operations2026-06-05
- Federal Register Proposed Rule: 21st Century Cures Act: Establishment of Disincentives for Health Care Providers That Have Committed Information Blocking2026-06-05
- Federal Register Final Rule: Medicare Program; Medicare Secondary Payer and Certain Civil Money Penalties2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Final Rule: Medicaid Program and CHIP; Mandatory Medicaid and Children's Health Insurance Program (CHIP) Core Set Reporting2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Proposed Rule: Request for Information; Episode-Based Payment Model2026-06-05
- Federal Register Notice: Request for Information Regarding Medical Payment Products2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Proposed Rule: Medicaid Program; Medicaid and Children's Health Insurance Program (CHIP) Managed Care Access, Finance, and Quality2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Proposed LCD DL35000: Molecular Pathology Procedures — NGS2026-06-05
- Proposed LCD DL39832: Botulinum Toxin Injections — NGS2026-06-05
- LCD L38568: MolDX: Molecular Testing for Solid Organ Allograft Rejection — Palmetto GBA2026-06-05
- LCD L38629: MolDX: Molecular Testing for Solid Organ Allograft Rejection — Noridian2026-06-05
- LCD L36704: ProMark® Risk Score — Noridian2026-06-05
- LCD L36706: ProMark® Risk Score — Noridian2026-06-05
- LCD L36675: ProMark® Risk Score — CGS2026-06-05
- LCD L35490: Category III Codes — WPS2026-06-05
- CMS Transmittal R13765FM: New Physician Specialty Code for Physician Nutrition Specialist (F7)2026-06-05
- CMS Transmittal R13765CP: The purpose of this Change Request (CR) is to establish a new physician code for Physician…2026-06-05
- CMS Transmittal R13783MSP: Creating Additional Medicare Secondary Payer (MSP) Error Codes to Better Identify Incoming MSP…2026-06-05
- CMS Transmittal R13784CP: October 2026 Healthcare Common Procedure Coding System (HCPCS) Quarterly Update Reminder2026-06-05
- CMS Transmittal R7P246i: This transmittal updates Chapter 46, Rural Health Clinic (RHC) Cost Report, FormCMS-222-17,…2026-06-05
- CMS Transmittal R9P244i: This transmittal updates Chapter 44, Federally Qualified Health Center (FQHC) Cost Report,…2026-06-05
- CMS Transmittal R13799CP: Updates to Publication 100-04, Chapter 4, Section 250.3.3.1 and 250.18 of the Internet Only…2026-06-05
- CMS Transmittal R13798OTN: Send 'Reason for Denial' Value in Prior Authorization Data to the Integrated Data Repository (…2026-06-05
- CMS Transmittal R13800NCD: NCD 20.37 - Transcatheter Tricuspid Valve Replacement (TTVR)2026-06-05
- CMS Transmittal R13802CP: NCD 20.40- Renal Denervation (RDN) for Uncontrolled Hypertension2026-06-05
- CMS Transmittal R13802NCD: NCD 20.40- Renal Denervation (RDN) for Uncontrolled Hypertension2026-06-05
- CMS Transmittal R13803CP: Rural Health Clinics (RHCs) and Federally Qualified Health Centers (FQHCs) Updates for Shared…2026-06-05
- CMS Transmittal R13808NCD: Noninvasive Positive Pressure Ventilation (NIPPV) in the Home for the Treatment of Chronic…2026-06-05
- CMS Transmittal R13808CP: Noninvasive Positive Pressure Ventilation (NIPPV) in the Home for the Treatment of Chronic…2026-06-05
- CMS Transmittal R242SOMA: Revisions to the State Operations Manual (SOM) Chapter 9 Exhibits.2026-06-05
- CMS Transmittal R13809CP: Update to the Internet Only Manual (IOM) Publication 100-04, Chapters 3, 13, 17, 18 and 32 for…2026-06-05
- FDA Approval: SANDIMMUNE (CYCLOSPORINE) — Type 3 - New Dosage Form2026-06-05
- FDA Approval: NDA 220482 — Type 1 - New Molecular Entity2026-06-05
- FDA Approval: NDA 220442 — Type 1 - New Molecular Entity2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Medicaid and Children's Health Insurance Program (CHIP) Generic Information Collection Activities: Proposed Collection; Reopening of Comment Period2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Healthcare Advisory Committee (HAC); Announcement of the HAC Meeting-May 18, 20262026-06-05
- Federal Register Notice: Medicare and Medicaid Programs; Quarterly Listing of Program Issuances-January through March 20262026-06-05
- Federal Register Notice: Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of Nationwide Temporary Moratoria on Enrollment of Home Health Agencies (HHAs)2026-06-05
- Federal Register Notice: Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of Nationwide Temporary Moratorium on Enrollment of Hospices2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Final Rule: Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program2026-06-05
- Federal Register Notice: Medicaid and Children's Health Insurance Program (CHIP) Generic Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Proposed Rule: Medicaid Program; Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Medicaid Practitioner Payments2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Final Rule: Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Final Rule: Notice of Vacatur Regarding Certain Provisions of the 2024 Nondiscrimination in Health Programs and Activities Final Rule2026-06-05
- Federal Register Final Rule: Medicaid Program; Community Engagement Requirement for Certain Individuals2026-06-05
- Reducing Bureaucracy and Burden for Family Assistance Programs2026-06-02
- Regulation for Federal Financial Assistance2026-06-02
- Medical Devices; Neurological Devices; Classification of the Transcutaneous Electrical Nerve Stimulator To Treat Fibromyalgia Symptoms2026-06-02
- Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program2026-06-02
- Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Suturing Device for Altering Gastric Anatomy for Weight Loss2026-06-02
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Rigid Sterilization Container With Electronic Monitoring2026-06-02
- Food Additive Petition From Environmental Defense Fund, et al.; Request To Amend the Food Additive Regulations To Remove the Solvents Benzene, Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period2026-06-02
- Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model2026-06-02
- Control of Communicable Diseases; Foreign Quarantine2026-06-02
- Color Additive Petition from Environmental Defense Fund, et al.; Request To Amend the Color Additive Regulations To Remove the Solvents Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period2026-06-02
- Medical Devices; Anesthesiology Devices; Classification of the Real-Time Ultrasound Anatomy Visualization and Labeling Device for Ultrasound Guided Regional Anesthesia2026-06-02
- Medical Devices; Dental Devices; Classification of the Intraoral Cooling Device2026-06-02
- Excepted Fertility Benefits2026-06-02
- Medical Devices; Gastroenterology-Urology Devices; Classification of the Orally Ingested Transient Device for Constipation2026-06-02
- Medical Devices; Anesthesiology Devices; Classification of the Adjunctive Pain Measurement Device for Anesthesiology2026-06-02
- Restoring Flexibility To Support Head Start Program Access2026-06-02
- Medical Devices; Ear, Nose, and Throat Devices; Classification of the Oropharyngeal Electrical Stimulator2026-06-02
- Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program for Federal Fiscal Year 20272026-06-02
- Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program2026-06-02
- Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program; Correction2026-06-02
- Contract Award for A/B MAC Jurisdiction N2026-06-02
- Contract Award for A/B MAC Jurisdiction 6 (posted 7/15/2020)2026-06-02
- Contract Award for A/B MAC Jurisdiction 152026-06-02
- Contract Award for A/B MAC Jurisdiction J2026-06-02
- Contract Award for A/B MAC Jurisdiction K (posted 12/15/2021)2026-06-02
- Contract Award for A/B MAC Jurisdiction 8 (posted 11/1/2018)2026-06-02
- Contract Award for A/B MAC Jurisdiction E (posted 12/18/2020)2026-06-02
- Contract Award for A/B MAC Jurisdiction J (posted 9/8/2017)2026-06-02
- Contract Award for A/B MAC Jurisdiction L (posted 7/27/2021)2026-06-02
- Contract Award for A/B MAC Jurisdiction M2026-06-02
- Contract Award for the DME Front End Common Electronic Data Interchange (posted 11/30/2017)2026-06-02
- Contract Award for A/B MAC Jurisdiction 5 (posted 9/20/2019)2026-06-02
- Contract Award for A/B MAC Jurisdiction F (posted 7/12/2018)2026-06-02
- Contract Award for A/B MAC Jurisdiction H (posted 5/30/2019)2026-06-02
- Contract Award for A/B MAC Jurisdiction J (posted 9/8/2017)2026-05-31
- Contract Award for A/B MAC Jurisdiction M2026-05-31
- Contract Award for A/B MAC Jurisdiction J2026-05-31
- Contract Award for A/B MAC Jurisdiction L (posted 7/27/2021)2026-05-31
- Contract Award for A/B MAC Jurisdiction K (posted 12/15/2021)2026-05-31
- Contract Award for A/B MAC Jurisdiction 5 (posted 9/20/2019)2026-05-31
- Contract Award for A/B MAC Jurisdiction N2026-05-31
- Contract Award for A/B MAC Jurisdiction 152026-05-31
- Contract Award for A/B MAC Jurisdiction E (posted 12/18/2020)2026-05-31
- Contract Award for the DME Front End Common Electronic Data Interchange (posted 11/30/2017)2026-05-31
- Contract Award for A/B MAC Jurisdiction F (posted 7/12/2018)2026-05-31
- Contract Award for A/B MAC Jurisdiction 8 (posted 11/1/2018)2026-05-31
- Contract Award for A/B MAC Jurisdiction H (posted 5/30/2019)2026-05-31
- Contract Award for A/B MAC Jurisdiction 6 (posted 7/15/2020)2026-05-31
Oncology170
- FDA Approval: RASONQUE (DARAXONRASIB) — Type 1 - New Molecular Entity2026-09-03
- FDA Approval: VOBRIG (LEUPROLIDE ACETATE) — Type 5 - New Formulation or New Manufacturer2026-09-03
- FDA Approval: LIBTAYO (CEMIPLIMAB-RWLC) — Type 1 - New Molecular Entity2026-09-03
- FDA Approval: BAVENCIO (AVELUMAB) — Type 1 - New Molecular Entity2026-09-03
- FDA Approval: UNLOXCYT (COSIBELIMAB) — Type 1 - New Molecular Entity2026-09-03
- FDA Approval: IMJUDO (TREMELIMUMAB) — Type 1 - New Molecular Entity2026-09-03
- FDA Approval: PENPULIMAB KCQX (PENPULIMAB) — Type 1 - New Molecular Entity2026-09-03
- FDA Approval: LOQTORZI (TORIPALIMAB-TPZI) — Type 1 - New Molecular Entity2026-09-03
- FDA Approval: TEVIMBRA (TISLELIZUMAB-JSGR) — Type 1 - New Molecular Entity2026-08-28
- FDA Approval: ZIIHERA (ZANIDATAMAB-HRII) — Type 1 - New Molecular Entity2026-08-28
- Proposed LCD DL40427: MolDX: Next-Generation Sequencing for Hematologic Malignancies and Suspected Hematologic Malignancies — Noridian2026-08-27
- Proposed LCD DL40435: MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal Carcinoma — Noridian2026-08-27
- Proposed LCD DL40411: MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic Neoplasms — Noridian2026-08-27
- Proposed LCD DL40431: MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic Neoplasms — CGS2026-08-27
- Proposed LCD DL40433: MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal Carcinoma — CGS2026-08-27
- Proposed LCD DL40451: MolDX: Next-Generation Sequencing for Hematologic Malignancies and Suspected Hematologic Malignancies — CGS2026-08-27
- Proposed LCD DL40407: MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic Neoplasms — Palmetto GBA2026-08-27
- Proposed LCD DL40429: MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal Carcinoma — Palmetto GBA2026-08-27
- Proposed LCD DL40425: MolDX: Next-Generation Sequencing for Hematologic Malignancies and Suspected Hematologic Malignancies — Palmetto GBA2026-08-27
- LCD L40226: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer — CGS2026-08-27
- LCD L40278: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer — WPS2026-08-27
- LCD L40210: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer — Palmetto GBA2026-08-27
- FDA Approval: ZELBORAF (VEMURAFENIB) — Type 1 - New Molecular Entity2026-08-26
- FDA Approval: COTELLIC (COBIMETINIB) — Type 1 - New Molecular Entity2026-08-26
- FDA Approval: OPDIVO (NIVOLUMAB) — Type 1 - New Molecular Entity2026-08-15
- FDA Approval: NEULASTA (PEGFILGRASTIM) — Type 1 - New Molecular Entity2026-08-08
- FDA Approval: HERNEXEOS (ZONGERTINIB) — Type 1 - New Molecular Entity2026-08-05
- FDA Approval: PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN) — Type 1 - New Molecular Entity2026-08-05
- FDA Approval: JIDEYTRO (ZIDESAMTINIB) — Type 1 - New Molecular Entity2026-07-29
- FDA Approval: XTANDI (ENZALUTAMIDE) — Type 1 - New Molecular Entity2026-07-29
- FDA Approval: XTANDI (ENZALUTAMIDE) — Type 3 - New Dosage Form2026-07-29
- FDA Approval: CAMCEVI ETM (LEUPROLIDE MESYLATE) — Type 5 - New Formulation or New Manufacturer2026-07-24
- LCD L39513: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin — Wellpoint Federal2026-07-24
- FDA Approval: NEUPOGEN (FILGRASTIM) — Type 1 - New Molecular Entity2026-07-23
- FDA Approval: MERCAPTOPURINE (MERCAPTOPURINE) — Type 5 - New Formulation or New Manufacturer2026-07-23
- FDA Approval: OGSIVEO (NIROGACESTAT) — Type 1 - New Molecular Entity2026-07-23
- LCD L37606: Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases — Wellpoint Federal2026-07-23
- LCD L38371: Multimarker Serum Tests Related to Ovarian Cancer Testing — Wellpoint Federal2026-07-23
- LCD L35075: Proton Beam Therapy — Wellpoint Federal2026-07-23
- FDA Approval: RETEVMO (SELPERCATINIB) — Type 1 - New Molecular Entity2026-07-18
- FDA Approval: REVTORPYK (GEDATOLISIB) — Type 1 - New Molecular Entity2026-07-18
- FDA Approval: RETEVMO (SELPERCATINIB) — Type 3 - New Dosage Form2026-07-18
- FDA Approval: VERZENIO (ABEMACICLIB) — Type 1 - New Molecular Entity2026-07-16
- FDA Approval: GLEEVEC (IMATINIB MESYLATE) — Type 3 - New Dosage Form2026-07-16
- FDA Approval: PADCEV EJFV (ENFORTUMAB VEDOTIN) — Type 1 - New Molecular Entity2026-07-15
- LCD L33826: Oral Anticancer Drugs — DME MAC2026-07-13
- FDA Approval: ERLEADA (APALUTAMIDE) — Type 1 - New Molecular Entity2026-07-08
- FDA Approval: TRUXIMA (RITUXIMAB-ABBS) — Type 5 - New Formulation or New Manufacturer2026-07-08
- FDA Approval: KISQALI FEMARA CO-PACK (LETROZOLE AND RIBOCICLIB) — Type 4 - New Combination2026-07-08
- FDA Approval: KISQALI (RIBOCICLIB) — Type 1 - New Molecular Entity2026-07-08
- FDA Approval: TRELSTAR (TRIPTORELIN PAMOATE) — Type 3 - New Dosage Form2026-07-01
- FDA Approval: TRELSTAR (TRIPTORELIN PAMOATE) — Type 3 - New Dosage Form2026-07-01
- FDA Approval: TRELSTAR (TRIPTORELIN PAMOATE) — Type 1 - New Molecular Entity2026-07-01
- FDA Approval: ROMVIMZA (VIMSELTINIB) — Type 1 - New Molecular Entity2026-07-01
- FDA Approval: NAVITRUX (FOSAPREPITANT) — Type 5 - New Formulation or New Manufacturer2026-06-30
- FDA Approval: ORSERDU (ELACESTRANT) — Type 1 - New Molecular Entity2026-06-30
- FDA Approval: ALECENSA (ALECTINIB HYDROCHLORIDE) — Type 1 - New Molecular Entity2026-06-17
- FDA Approval: WELIREG (BELZUTIFAN) — Type 1 - New Molecular Entity2026-06-17
- FDA Approval: KEYTRUDA QLEX (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH) — Type 1 - New Molecular Entity2026-06-17
- FDA Approval: TZIELD (TEPLIZUMAB-MZWV) — Type 1 - New Molecular Entity2026-06-17
- FDA Approval: KEYTRUDA (PEMBROLIZUMAB) — Type 1 - New Molecular Entity2026-06-17
- FDA Approval: YERVOY (IPILIMUMAB) — Type 1 - New Molecular Entity2026-06-17
- FDA Approval: OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW) — Type 1 - New Molecular Entity2026-06-13
- FDA Approval: VORANIGO (VORASIDENIB) — Type 1 - New Molecular Entity2026-06-13
- FDA Approval: HYMPAVZI (MARSTACIMAB-HNCQ) — Type 1 - New Molecular Entity2026-06-11
- Proposed LCD DL39927: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian2026-06-05
- Proposed LCD DL39297: Off-label Use of Rituximab and Rituximab Biosimilars — NGS2026-06-05
- Proposed LCD DL40142: MolDX: Biomarker Testing for Risk Stratification in DCIS — Palmetto GBA2026-06-05
- Proposed LCD DL40246: MolDX: Biomarker Testing for Risk Stratification in DCIS — CGS2026-06-05
- Proposed LCD DL40144: MolDX: Biomarker Testing for Risk Stratification in DCIS — Noridian2026-06-05
- Proposed LCD DL40251: MolDX: Biomarker Testing for Risk Stratification in DCIS — WPS2026-06-05
- Proposed LCD DL40210: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer — Palmetto GBA2026-06-05
- Proposed LCD DL40226: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer — CGS2026-06-05
- Proposed LCD DL40222: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer — Noridian2026-06-05
- Proposed LCD DL40278: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer — WPS2026-06-05
- Proposed LCD DL40205: Irreversible Electroporation for Cancer — Palmetto GBA2026-06-05
- LCD L37794: MolDX: Breast Cancer Index® (BCI) Gene Expression Test — Palmetto GBA2026-06-05
- LCD L38238: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer — Palmetto GBA2026-06-05
- LCD L38292: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — Palmetto GBA2026-06-05
- LCD L38566: MolDX: Phenotypic Biomarker Detection in Circulating Tumor Cells — Palmetto GBA2026-06-05
- LCD L38985: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Palmetto GBA2026-06-05
- LCD L39297: Off-label Use of Rituximab and Rituximab Biosimilars — NGS2026-06-05
- LCD L36797: MolDX: NRAS Genetic Testing — WPS2026-06-05
- LCD L38678: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells — WPS2026-06-05
- LCD L38920: Off-label Use of Rituximab and Rituximab Biosimilars — CGS2026-06-05
- LCD L36113: MolDX: MGMT Promoter Methylation Analysis — CGS2026-06-05
- LCD L38067: MolDX: Next-Generation Sequencing for Solid Tumors — CGS2026-06-05
- LCD L35442: MolDX: NRAS Genetic Testing — CGS2026-06-05
- LCD L37001: MolDX: MGMT Promoter Methylation Analysis — WPS2026-06-05
- LCD L36951: MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™) — CGS2026-06-05
- LCD L36658: Proton Beam Therapy — CGS2026-06-05
- LCD L37628: In Vitro Chemosensitivity & Chemoresistance Assays — Noridian2026-06-05
- LCD L37630: In Vitro Chemosensitivity & Chemoresistance Assays — Noridian2026-06-05
- LCD L37832: MolDX: Breast Cancer Index® (BCI) Gene Expression Test — CGS2026-06-05
- LCD L38835: MolDX: Minimal Residual Disease Testing for Cancer — WPS2026-06-05
- LCD L37199: MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™) — WPS2026-06-05
- LCD L36678: Lab: Bladder/Urothelial Tumor Markers — Noridian2026-06-05
- LCD L38822: MolDX: Minimal Residual Disease Testing for Cancer — CGS2026-06-05
- LCD L38284: MolDX: Predictive Classifiers for Early Stage Non-small Cell Lung Cancer — CGS2026-06-05
- LCD L36680: Lab: Bladder/Urothelial Tumor Markers — Noridian2026-06-05
- LCD L37921: MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer — WPS2026-06-05
- LCD L39553: Radiation Therapies — Palmetto GBA2026-06-05
- LCD L34648: Bisphosphonate Drug Therapy — WPS2026-06-05
- LCD L39686: MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers — Noridian2026-06-05
- LCD L37897: MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer — Noridian2026-06-05
- LCD L37822: MolDX: Breast Cancer Index® (BCI) Gene Expression Test — Noridian2026-06-05
- LCD L37295: MolDX: EndoPredict® Breast Cancer Gene Expression Test — Noridian2026-06-05
- LCD L37070: MolDX: DecisionDx-UM (Uveal Melanoma) — Noridian2026-06-05
- LCD L36380: MolDX: Breast Cancer Assay: Prosigna® — Noridian2026-06-05
- LCD L39005: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Noridian2026-06-05
- LCD L37750: MolDX: Melanoma Risk Stratification Molecular Testing — Noridian2026-06-05
- LCD L36188: MolDX: MGMT Promoter Methylation Analysis — Noridian2026-06-05
- LCD L39375: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma — Noridian2026-06-05
- LCD L39007: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Noridian2026-06-05
- LCD L37899: MolDX: Inivata™, InvisionFirst®, Liquid Biopsy for Patients with Lung Cancer — Noridian2026-06-05
- LCD L37824: MolDX: Breast Cancer Index® (BCI) Gene Expression Test — Noridian2026-06-05
- LCD L37748: MolDX: Melanoma Risk Stratification Molecular Testing — Noridian2026-06-05
- LCD L37311: MolDX: EndoPredict® Breast Cancer Gene Expression Test — Noridian2026-06-05
- LCD L37072: MolDX: DecisionDx-UM (Uveal Melanoma) — Noridian2026-06-05
- LCD L36386: MolDX: Breast Cancer Assay: Prosigna® — Noridian2026-06-05
- LCD L36192: MolDX: MGMT Promoter Methylation Analysis — Noridian2026-06-05
- LCD L38972: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer — Noridian2026-06-05
- LCD L38814: MolDX: Minimal Residual Disease Testing for Cancer — Noridian2026-06-05
- LCD L39230: MolDX: Plasma-Based Genomic Profiling in Solid Tumors — Noridian2026-06-05
- LCD L38643: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells — Noridian2026-06-05
- LCD L38327: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer — Noridian2026-06-05
- LCD L38123: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies — Noridian2026-06-05
- LCD L38119: MolDX: Next-Generation Sequencing for Solid Tumors — Noridian2026-06-05
- LCD L36941: MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™) — Noridian2026-06-05
- LCD L36335: MolDX: NRAS Genetic Testing — Noridian2026-06-05
- LCD L38351: MolDX: Repeat Germline Testing — Noridian2026-06-05
- LCD L38339: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — Noridian2026-06-05
- LCD L39232: MolDX: Plasma-Based Genomic Profiling in Solid Tumors — Noridian2026-06-05
- LCD L38974: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer — Noridian2026-06-05
- LCD L38816: MolDX: Minimal Residual Disease Testing for Cancer — Noridian2026-06-05
- LCD L38649: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer — Noridian2026-06-05
- LCD L38645: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells — Noridian2026-06-05
- LCD L38341: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — Noridian2026-06-05
- LCD L38329: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer — Noridian2026-06-05
- LCD L38125: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies — Noridian2026-06-05
- LCD L38121: MolDX: Next-Generation Sequencing for Solid Tumors — Noridian2026-06-05
- LCD L36947: MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™) — Noridian2026-06-05
- LCD L36339: MolDX: NRAS Genetic Testing — Noridian2026-06-05
- LCD L38065: MolDX: Plasma-Based Genomic Profiling in Solid Tumors — CGS2026-06-05
- LCD L38288: MolDX: Repeat Germline Testing — CGS2026-06-05
- LCD L37913: MolDX: Breast Cancer Index® (BCI) Gene Expression Test — WPS2026-06-05
- LCD L38176: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies — WPS2026-06-05
- LCD L36425: MolDX: Breast Cancer Assay: Prosigna® — CGS2026-06-05
- LCD L39017: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer — CGS2026-06-05
- LCD L38303: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — CGS2026-06-05
- LCD L39040: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer — WPS2026-06-05
- LCD L39389: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma — CGS2026-06-05
- LCD L37356: MolDX: EndoPredict Breast Cancer Gene Expression Test — CGS2026-06-05
- LCD L38584: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells — CGS2026-06-05
- Proposed LCD DL34356: Erythropoiesis Stimulating Agents (ESA) — CGS2026-06-05
- LCD L37810: Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms — NGS2026-06-05
- LCD L38586: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer — CGS Administrators2026-06-05
- LCD L40205: Irreversible Electroporation for Cancer — Palmetto GBA2026-06-05
- LCD L39614: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma — WPS2026-06-05
- LCD L37210: MolDX: Decision Dx-UM (Uveal Melanoma) — WPS2026-06-05
- LCD L39585: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma — CGS Administrators2026-06-05
- FDA Approval: TRUQAP (CAPIVASERTIB) — Type 1 - New Molecular Entity2026-06-05
- FDA Approval: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — Type 1 - New Molecular Entity2026-06-05
- FDA Approval: DECNUPAZ (PIVEKIMAB SUNIRINE-PVZY) — Type 1 - New Molecular Entity2026-06-05
- FDA Approval: XATMEP (METHOTREXATE) — Type 3 - New Dosage Form2026-06-05
- FDA Approval: IMFINZI (DURVALUMAB) — Type 1 - New Molecular Entity2026-06-05
- FDA Approval: DARZALEX (DARATUMUMAB) — Type 1 - New Molecular Entity2026-06-05
- FDA Approval: COLUMVI (GLOFITAMAB) — Type 1 - New Molecular Entity2026-06-05
- FDA Approval: HEPZATO KIT (MELPHALAN HYDROCHLORIDE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) — Type 4 - New Combination2026-06-05
- FDA Approval: NDA 217379 — Type 5 - New Formulation or New Manufacturer2026-06-05
Pain Management90
- FDA Approval: TYLENOL WITH NAPROXEN (NAPROXEN SODIUM, ACETAMINOPHEN) — Type 4 - New Combination2026-07-29
- LCD L36850: Peripheral Nerve Blocks — Wellpoint Federal2026-07-23
- LCD L33622: Pain Management - Injection of tendon sheaths, ligaments, ganglion cysts, carpal and tarsal tunnels — Wellpoint Federal2026-07-23
- LCD L39662: Trigger Point Injections (TPI) — Wellpoint Federal2026-07-23
- LCD L39455: Sacroiliac Joint Injections and Procedures — Wellpoint Federal2026-07-23
- LCD L35010: Trigger Point Injections — Novitas2026-07-23
- LCD L33912: Trigger Point Injections — First Coast2026-07-23
- Proposed LCD DL34892: Facet Joint Interventions for Pain Management — Novitas2026-07-10
- Proposed LCD DL33930: Facet Joint Interventions for Pain Management — First Coast2026-07-10
- FDA Approval: DEMEROL (MEPERIDINE HYDROCHLORIDE) — Type 1 - New Molecular Entity2026-06-25
- FDA Approval: SYNALGOS-DC (ASPIRIN) — Type 4 - New Combination2026-06-25
- FDA Approval: TAPENTADOL (TAPENTADOL HYDROCHLORIDE) — Type 1 - New Molecular Entity2026-06-24
- FDA Approval: OXAYDO (OXYCODONE HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer2026-06-24
- FDA Approval: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — Type 7 - Drug Already Marketed without Approved NDA2026-06-24
- FDA Approval: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — Type 7 - Drug Already Marketed without Approved NDA2026-06-24
- FDA Approval: TAPENTADOL (TAPENTADOL HYDROCHLORIDE) — Type 3 - New Dosage Form2026-06-23
- FDA Approval: MS CONTIN (MORPHINE SULFATE) — Type 3 - New Dosage Form2026-06-23
- FDA Approval: XTAMPZA ER (OXYCODONE) — Type 5 - New Formulation or New Manufacturer2026-06-23
- FDA Approval: OXYCONTIN (OXYCODONE HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer2026-06-23
- Proposed LCD DL33274: Botulinum Toxins — First Coast2026-06-05
- Proposed LCD DL40300: Peripheral Nerve Blocks and Procedures for Chronic Pain — WPS2026-06-05
- Proposed LCD DL40265: Peripheral Nerve Blocks and Procedures for Chronic Pain — Noridian2026-06-05
- Proposed LCD DL40261: Peripheral Nerve Blocks and Procedures for Chronic Pain — CGS2026-06-05
- Proposed LCD DL40267: Peripheral Nerve Blocks and Procedures for Chronic Pain — NGS2026-06-05
- Proposed LCD DL33622: Pain Management - Injection of tendon sheaths, ligaments, bursa, and ganglion cysts — NGS2026-06-05
- Proposed LCD DL40263: Peripheral Nerve Blocks and Procedures for Chronic Pain — Palmetto GBA2026-06-05
- Proposed LCD DL40302: Thermal Destruction of the Intraosseous Basivertebral Nerve (BVN) for Vertebrogenic Lower Back Pain — NGS2026-06-05
- Proposed LCD DL35010: Trigger Point Injections — Novitas2026-06-05
- Proposed LCD DL33912: Trigger Point Injections — First Coast2026-06-05
- Proposed LCD DL35170: Botulinum Toxin Injections — Noridian2026-06-05
- Proposed LCD DL39909: Botulinum Toxin Injections — WPS2026-06-05
- Proposed LCD DL35172: Botulinum Toxin Injections — Noridian2026-06-05
- Proposed LCD DL39836: Botulinum Toxin Injections — Palmetto GBA2026-06-05
- LCD L36668: Urine Drug Testing — Noridian2026-06-05
- LCD L36707: Urine Drug Testing — Noridian2026-06-05
- LCD L34645: Urine Drug Testing — WPS2026-06-05
- LCD L38902: Wound and Ulcer Care — Noridian2026-06-05
- LCD L39242: Epidural Steroid Injections for Pain Management — Noridian2026-06-05
- LCD L39060: Platelet Rich Plasma Injections for Non-Wound Injections — Noridian2026-06-05
- LCD L39624: Amniotic and Placental Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound — WPS2026-06-05
- LCD L38809: Botulinum Toxins — Novitas2026-06-05
- LCD L33274: Botulinum Toxins — First Coast2026-06-05
- LCD L35136: Spinal Cord Stimulators for Chronic Pain — Noridian2026-06-05
- LCD L39116: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound — Noridian2026-06-05
- LCD L34328: Peripheral Nerve Stimulation — Noridian2026-06-05
- LCD L34211: Trigger Point Injections (TPI) — Noridian2026-06-05
- LCD L36204: Spinal Cord Stimulators for Chronic Pain — Noridian2026-06-05
- LCD L37360: Peripheral Nerve Stimulation — Noridian2026-06-05
- LCD L36859: Trigger Point Injections (TPI) — Noridian2026-06-05
- LCD L35170: Botulinum Toxin Injections — Noridian2026-06-05
- LCD L35172: Botulinum Toxin Injections — Noridian2026-06-05
- LCD L39832: Botulinum Toxin Injections — NGS2026-06-05
- LCD L39836: Botulinum Toxin Injections — Palmetto GBA2026-06-05
- LCD L39857: Botulinum Toxin Injections — CGS2026-06-05
- LCD L39713: Trigger Point Injections — WPS2026-06-05
- LCD L39616: Urinary Biomarkers for Chronic Pain Management — CGS2026-06-05
- LCD L37254: Chiropractic Services — CGS2026-06-05
- LCD L33458: Chemodenervation — Palmetto GBA2026-06-05
- LCD L34635: Botulinum Toxin Type A & Type B — WPS2026-06-05
- LCD L33949: Botulinum Toxins — CGS2026-06-05
- LCD L33646: Botulinum Toxins — NGS2026-06-05
- LCD L39642: Intraosseous Basivertebral Nerve Ablation — Noridian2026-06-05
- LCD L39462: Sacroiliac Joint Injections and Procedures — Noridian2026-06-05
- LCD L35456: Nerve Blockade for Treatment of Chronic Pain and Neuropathy — Noridian2026-06-05
- LCD L36029: Urine Drug Testing — CGS2026-06-05
- LCD L35457: Nerve Blockade for Treatment of Chronic Pain and Neuropathy — Noridian2026-06-05
- LCD L39464: Sacroiliac Joint Injections and Procedures — Noridian2026-06-05
- LCD L39644: Intraosseous Basivertebral Nerve Ablation — Noridian2026-06-05
- LCD L39909: Botulinum Toxin Injections — WPS2026-06-05
- LCD L39383: Sacroiliac Joint Injections and Procedures — CGS2026-06-05
- LCD L38765: Facet Joint Interventions for Pain Management — Palmetto GBA2026-06-05
- LCD L35936: Facet Joint Interventions for Pain Management — NGS2026-06-05
- LCD L38801: Facet Joint Interventions for Pain Management — Noridian2026-06-05
- LCD L37873: Topical Oxygen Therapy — Palmetto GBA2026-06-05
- LCD L38994: Epidural Steroid Injections for Pain Management — Palmetto GBA2026-06-05
- LCD L37166: Wound Care — First Coast2026-06-05
- LCD L36920: Epidural Steroid Injections for Pain Management — Novitas2026-06-05
- LCD L33906: Epidural Steroid Injections for Pain Management — First Coast2026-06-05
- LCD L39015: Epidural Steroid Injections for Pain Management — CGS2026-06-05
- LCD L38803: Facet Joint Interventions for Pain Management — Noridian2026-06-05
- Proposed LCD DL39857: Botulinum Toxin Injections — CGS2026-06-05
- LCD L39054: Epidural Steroid Injections for Pain Management — WPS2026-06-05
- LCD L35249: Nerve Blocks for Peripheral Neuropathy — CGS2026-06-05
- LCD L39036: Epidural Steroid Injections for Pain Management — NGS2026-06-05
- LCD L39240: Epidural Steroid Injections for Pain Management — Noridian2026-06-05
- LCD L40302: Thermal Destruction of the Intraosseous Basivertebral Nerve (BVN) for Vertebrogenic Lower Back Pain — NGS2026-06-05
- LCD L36000: Percutaneous minimally invasive fusion/stabilization of the sacroiliac joint for the treatment of back pain — WPS2026-06-05
- LCD L38841: Facet Joint Interventions for Pain Management — WPS2026-06-05
- LCD L38773: Facet Joint Interventions for Pain Management — CGS Administrators2026-06-05
- FDA Approval: MORPHINE SULFATE (MORPHINE SULFATE) — Type 5 - New Formulation or New Manufacturer2026-06-05
Cardiology80
- FDA Approval: HEMANGEOL (PROPRANOLOL HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer2026-09-03
- FDA Approval: LEQVIO (INCLISIRAN) — Type 1 - New Molecular Entity2026-08-26
- FDA Approval: LEROCHOL (LERODALCIBEP-LIGA) — Type 1 - New Molecular Entity2026-08-20
- FDA Approval: INPEFA (SOTAGLIFLOZIN) — Type 1 - New Molecular Entity2026-08-12
- FDA Approval: TRYVIO (APROCITENTAN) — Type 1 - New Molecular Entity2026-08-11
- FDA Approval: FUROSCIX (FUROSEMIDE INJECTION 80 MG/ 10 ML) — Type 3 - New Dosage Form2026-07-29
- FDA Approval: BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE (BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE) — Type 4 - New Combination2026-07-29
- FDA Approval: AVAPRO (IRBESARTAN) — Type 1 - New Molecular Entity2026-07-29
- LCD L33560: Cardiovascular Nuclear Medicine — Wellpoint Federal2026-07-24
- LCD L33559: Cardiac Computed Tomography (CCT) and Coronary Computed Tomography Angiography (CCTA) — Wellpoint Federal2026-07-24
- LCD L39863: Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA) — Wellpoint Federal2026-07-24
- FDA Approval: ENLICITIDE (ENLICITIDE CHLORIDE) — Type 1 - New Molecular Entity2026-07-23
- LCD L33627: Non-Invasive Vascular Studies — Wellpoint Federal2026-07-23
- LCD L39075: Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease — Wellpoint Federal2026-07-23
- LCD L33623: Percutaneous Coronary Intervention — Wellpoint Federal2026-07-23
- LCD L33577: Transthoracic Echocardiography (TTE) — Wellpoint Federal2026-07-23
- LCD L33579: Transesophageal Echocardiography (TEE) — Wellpoint Federal2026-07-23
- FDA Approval: REPATHA (EVOLOCUMAB) — Type 1 - New Molecular Entity2026-07-18
- FDA Approval: ELIQUIS (APIXABAN) — Type 1 - New Molecular Entity2026-06-30
- FDA Approval: ELIQUIS (APIXABAN) — Type 3 - New Dosage Form2026-06-30
- FDA Approval: ARGATROBAN IN SODIUM CHLORIDE (ARGATROBAN) — Type 5 - New Formulation or New Manufacturer2026-06-13
- LCD L40255: Temporary Nontherapeutic Ambulatory Cardiac Monitoring Devices — Noridian2026-06-06
- LCD L40257: Temporary Nontherapeutic Ambulatory Cardiac Monitoring Devices — Palmetto GBA2026-06-06
- LCD L40244: Temporary Nontherapeutic Ambulatory Cardiac Monitoring Devices — CGS2026-06-06
- Proposed LCD DL34410: B-type Natriuretic Peptide (BNP) Testing — Palmetto GBA2026-06-05
- Proposed LCD DL40244: Temporary Nontherapeutic Ambulatory Cardiac Monitoring Devices — CGS2026-06-05
- Proposed LCD DL40255: Temporary Nontherapeutic Ambulatory Cardiac Monitoring Devices — Noridian2026-06-05
- Proposed LCD DL40228: Endovascular Management for Peripheral Arterial Disease of the Upper and Lower Extremities — Palmetto GBA2026-06-05
- Proposed LCD DL40257: Temporary Nontherapeutic Ambulatory Cardiac Monitoring Devices — Palmetto GBA2026-06-05
- LCD L33423: Cardiac Computed Tomography & Angiography (CCTA) — Palmetto GBA2026-06-05
- LCD L39938: MolDX: Genetic Testing for Heritable Thoracic Aortic Disease — CGS2026-06-05
- LCD L39933: MolDX: Genetic Testing for Heritable Thoracic Aortic Disease — Palmetto GBA2026-06-05
- LCD L39989: MolDX: Genetic Testing for Heritable Thoracic Aortic Disease — WPS2026-06-05
- LCD L34551: One Day Stays for Chest Pain — Palmetto GBA2026-06-05
- LCD L34636: Electrocardiographic (EKG or ECG) Monitoring (Holter or Real-Time Monitoring) — WPS2026-06-05
- LCD L38771: Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease — CGS2026-06-05
- LCD L34084: Transcatheter Infusion Therapy — CGS2026-06-05
- LCD L34087: Surveillance of Implantable or Wearable Cardioverter Defibrillators (ICDs): Office, Hospital, Web, or Non-Web Based — CGS2026-06-05
- LCD L34337: Transesophageal Echocardiography (TEE) — CGS2026-06-05
- LCD L34338: Transthoracic Echocardiography (TTE) — CGS2026-06-05
- LCD L33947: Cardiac Computed Tomography (CCT) and Coronary Computed Tomography Angiography (CCTA) — CGS2026-06-05
- LCD L39881: Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT )/Coronary Plaque Analysis (AI-CPA) — Noridian2026-06-05
- LCD L34324: Cardiovascular Stress Testing, Including Exercise and/or Pharmacological Stress and Stress Echocardiography — Noridian2026-06-05
- LCD L36889: Cardiovascular Stress Testing, Including Exercise and/or Pharmacological Stress and Stress Echocardiography — Noridian2026-06-05
- LCD L39883: Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT )/Coronary Plaque Analysis (AI-CPA) — Noridian2026-06-05
- LCD L37379: Echocardiography — Palmetto GBA2026-06-05
- LCD L34761: Percutaneous Coronary Interventions — WPS2026-06-05
- LCD L35121: Coronary Computed Tomography Angiography (CCTA) — WPS2026-06-05
- LCD L35998: Non-Coronary Vascular Stents — WPS2026-06-05
- LCD L34315: Electrocardiograms — Noridian2026-06-05
- LCD L33959: Cardiac Catheterization and Coronary Angiography — CGS2026-06-05
- LCD L37283: Electrocardiograms — Noridian2026-06-05
- LCD L33557: Cardiac Catheterization and Coronary Angiography — NGS2026-06-05
- LCD L33943: B-type Natriuretic Peptide (BNP) Testing — CGS2026-06-05
- LCD L33952: Cardiac Event Detection — CGS2026-06-05
- LCD L38786: Echocardiography for Myocardial Perfusion — Palmetto GBA2026-06-05
- LCD L34410: B-type Natriuretic Peptide (BNP) Testing — Palmetto GBA2026-06-05
- LCD L36358: MolDX: Biomarkers in Cardiovascular Risk Assessment — Noridian2026-06-05
- LCD L39944: MolDX: Genetic Testing for Heritable Thoracic Aortic Disease — Noridian2026-06-05
- LCD L39946: MolDX: Genetic Testing for Heritable Thoracic Aortic Disease — Noridian2026-06-05
- LCD L36362: MolDX: Biomarkers in Cardiovascular Risk Assessment — Noridian2026-06-05
- LCD L35761: Non-Invasive Peripheral Arterial Vascular Studies — WPS2026-06-05
- LCD L37126: Coenzyme Q10 (CoQ10) — CGS2026-06-05
- LCD L33422: Brain Natriuretic Peptide (BNP) Level — Palmetto GBA2026-06-05
- LCD L36523: MolDX: Biomarkers in Cardiovascular Risk Assessment — WPS2026-06-05
- LCD L40228: Endovascular Management for Peripheral Arterial Disease of the Upper and Lower Extremities — Palmetto GBA2026-06-05
- LCD L33960: Cardiovascular Nuclear Medicine — CGS2026-06-05
- LCD L35526: B-type Natriuretic Peptide (BNP) Testing — Noridian2026-06-05
- LCD L38613: Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease — Noridian2026-06-05
- LCD L34038: B-type Natriuretic Peptide (BNP) Testing — Noridian2026-06-05
- LCD L38615: Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease — Noridian2026-06-05
- LCD L36139: MolDX: Biomarkers in Cardiovascular Risk Assessment — CGS2026-06-05
- LCD L34573: Cardiac Event Detection — Palmetto GBA2026-06-05
- LCD L38839: Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease — WPS2026-06-05
- CMS Transmittal R13800CP: NCD 20.37 - Transcatheter Tricuspid Valve Replacement (TTVR)2026-06-05
- CMS Transmittal R13801CP: NCD 20.38 - Transcatheter Edge-to-Edge Repair for Tricuspid Valve Regurgitation (T-TEER)2026-06-05
- CMS Transmittal R13801NCD: NCD 20.38 - Transcatheter Edge-to-Edge Repair for Tricuspid Valve Regurgitation (T-TEER)2026-06-05
- CMS Transmittal R13806NCD: Cardiac Contractility Modulation (CCM) for Heart Failure (HF)2026-06-05
- CMS Transmittal R13806CP: Cardiac Contractility Modulation (CCM) for Heart Failure (HF)2026-06-05
- FDA Approval: WIDAPLIK (TELMISARTAN, AMLODIPINE AND INDAPAMIDE) — Type 4 - New Combination2026-06-05
Clinical Laboratory78
- LCD L38680: MolDx: Molecular Testing for Solid Organ Allograft Rejection — WPS2026-09-03
- LCD L40274: MolDX: Genetic Testing for Hereditary Thrombophilia — WPS2026-08-27
- LCD L40259: MolDX: Genetic Testing for Hereditary Thrombophilia — CGS2026-08-27
- LCD L40222: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer — Noridian2026-08-27
- LCD L40242: MolDX: Genetic Testing for Hereditary Thrombophilia — Noridian2026-08-27
- LCD L40238: MolDX: Genetic Testing for Hereditary Thrombophilia — Palmetto GBA2026-08-27
- CMS Transmittal R13921CP: NCD 210.3 Screening for Colorectal Cancer-Non-Invasive Biomarker Tests2026-08-27
- CMS Transmittal R13921NCD: NCD 210.3 Screening for Colorectal Cancer-Non-Invasive Biomarker Tests2026-08-27
- CMS Transmittal R13884CP: October 2026 Quarterly Update to the Clinical Laboratory Fee Schedule (CLFS) and Clinical…2026-08-25
- LCD L33573: B-type Natriuretic Peptide (BNP) Testing — Wellpoint Federal2026-07-24
- LCD L35074: Heavy Metal Testing — Wellpoint Federal2026-07-23
- LCD L39189: Mass Spectrometry (MS) Testing in Monoclonal Gammopathy (MG) — Wellpoint Federal2026-07-23
- LCD L39726: KidneyIntelX and KidneyIntelX.dkd Testing — Wellpoint Federal2026-07-23
- LCD L39995: Pharmacogenomic Testing — Wellpoint Federal2026-07-23
- LCD L39611: Urine Drug Testing — Wellpoint Federal2026-07-23
- LCD L37535: Vitamin D Assay Testing — Wellpoint Federal2026-07-23
- LCD L33591: RAST Type Tests — Wellpoint Federal2026-07-23
- LCD L40058: MolDX: Molecular Testing for Solid Organ Allograft Rejection — Palmetto GBA2026-07-16
- LCD L40060: MolDX: Molecular Testing for Solid Organ Allograft Rejection — Noridian2026-07-16
- LCD L40062: MolDX: Molecular Testing for Solid Organ Allograft Rejection — Noridian2026-07-16
- LCD L40249: MolDX: Molecular Testing for Solid Organ Allograft Rejection — WPS2026-07-16
- LCD L40140: MolDX: Molecular Testing for Solid Organ Allograft Rejection — CGS2026-07-16
- CMS Transmittal R13849CP: Changes to the Laboratory National Coverage Determination (NCD) Edit Software for October 2026…2026-07-03
- CMS Transmittal R13855CP: July 2026 Quarterly Update to the Clinical Laboratory Fee Schedule (CLFS) and Clinical…2026-07-03
- LCD L40272 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — WPS2026-06-25
- LCD L40199 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — CGS Administrators2026-06-25
- LCD L40197 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Noridian2026-06-25
- LCD L40187 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Palmetto GBA2026-06-25
- Federal Register Notice: Medicare Program: Public Meeting Regarding New and Reconsidered Clinical Diagnostic Laboratory Test Codes for the Clinical Laboratory Fee Schedule for Calendar Year 20272026-06-05
- Federal Register Notice: Medicare Program: Public Meeting Regarding New and Reconsidered Clinical Diagnostic Laboratory Test Codes for the Clinical Laboratory Fee Schedule for Calendar Year 2026-June 27, 20252026-06-05
- Federal Register Notice: Public Meeting on June 25, 2024 Regarding New and Reconsidered Clinical Diagnostic Laboratory Test Codes for the Clinical Laboratory Fee Schedule for Calendar Year 20252026-06-05
- Federal Register Notice: Medicare Program; Public Meeting on June 22, 2023 Regarding New and Reconsidered Clinical Diagnostic Laboratory Test Codes for the Clinical Laboratory Fee Schedule for Calendar Year 20242026-06-05
- Proposed LCD DL36351: Lab: Special Histochemical Stains and Immunohistochemical Stains — Noridian2026-06-05
- Proposed LCD DL36353: Lab: Special Histochemical Stains and Immunohistochemical Stains — Noridian2026-06-05
- Proposed LCD DL40058: MolDX: Molecular Testing for Solid Organ Allograft Rejection — Palmetto GBA2026-06-05
- Proposed LCD DL40140: MolDX: Molecular Testing for Solid Organ Allograft Rejection — CGS2026-06-05
- Federal Register Final Rule: Clinical Laboratory Improvement Amendments of 1988 (CLIA) Fees; Histocompatibility, Personnel, and Alternative Sanctions for Certificate of Waiver Laboratories2026-06-05
- LCD L39935: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis — Palmetto GBA2026-06-05
- LCD L34011: Ionized Calcium — First Coast2026-06-05
- LCD L33996: Vitamin D Assay Testing — CGS2026-06-05
- LCD L36692: Vitamin D Assay Testing — Noridian2026-06-05
- LCD L34051: Vitamin D Assay Testing — Noridian2026-06-05
- LCD L36021: MolDX: Molecular Diagnostic Tests (MDT) — CGS2026-06-05
- LCD L34658: Vitamin D Assay Testing — WPS2026-06-05
- LCD L37616: Lab: Cystatin C Measurement — Noridian2026-06-05
- LCD L36351: Lab: Special Histochemical Stains and Immunohistochemical Stains — Noridian2026-06-05
- LCD L36353: Lab: Special Histochemical Stains and Immunohistochemical Stains — Noridian2026-06-05
- LCD L37618: Lab: Cystatin C Measurement — Noridian2026-06-05
- LCD L38294: MolDX: Pharmacogenomics Testing — Palmetto GBA2026-06-05
- LCD L38435: MolDX: Pharmacogenomics Testing — WPS2026-06-05
- LCD L37066: Lab: Coenzyme Q10 (CoQ10) — Noridian2026-06-05
- LCD L36702: Serum Magnesium — Noridian2026-06-05
- LCD L37620: MDS FISH — Noridian2026-06-05
- LCD L36700: Serum Magnesium — Noridian2026-06-05
- LCD L37068: Lab: Coenzyme Q10 (CoQ10) — Noridian2026-06-05
- LCD L38394: MolDX: Pharmacogenomics Testing — CGS2026-06-05
- LCD L37622: MDS FISH — Noridian2026-06-05
- LCD L37062: BDX-XL2 — Noridian2026-06-05
- LCD L34215: Lab: Flow Cytometry — Noridian2026-06-05
- LCD L36094: Lab: Flow Cytometry — Noridian2026-06-05
- LCD L37598: Cystatin C Measurement — CGS2026-06-05
- LCD L37602: MDS FISH — Palmetto GBA2026-06-05
- LCD L39391: Vitamin D Assay Testing — Palmetto GBA2026-06-05
- LCD L37608: MDS FISH — CGS2026-06-05
- LCD L35160: MolDX: Molecular Diagnostic Tests (MDT) — Noridian2026-06-05
- LCD L39950: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis — Noridian2026-06-05
- LCD L38353: MolDX: Repeat Germline Testing — Noridian2026-06-05
- LCD L36256: MolDX: Molecular Diagnostic Tests (MDT) — Noridian2026-06-05
- LCD L38070: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies — CGS2026-06-05
- LCD L38335: MolDX: Pharmacogenomics Testing — Noridian2026-06-05
- LCD L35986: Special Histochemical Stains and Immunohistochemical Stains — CGS2026-06-05
- LCD L34037: Flow Cytometry — CGS2026-06-05
- LCD L38337: MolDX: Pharmacogenomics Testing — Noridian2026-06-05
- LCD L39940: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis — CGS2026-06-05
- LCD L36805: Lab: Special Histochemical Stains and Immunohistochemical Stains — WPS2026-06-05
- LCD L35000: Molecular Pathology Procedures — NGS2026-06-05
- CMS Transmittal R13807CP: July 2026 Quarterly Update to the Clinical Laboratory Fee Schedule (CLFS) and Clinical…2026-06-05
- 2026 Clinical Laboratory Fee Schedule2026-06-02
DME76
- CMS Transmittal R13937CP: Annual Clotting Factor Furnishing Fee Update 20272026-08-27
- CMS Transmittal R13889BP: Update to Pub. 100-02 Medicare Benefit Policy Manual, Chapter 15, Section 110.8 Durable Medical…2026-07-31
- Proposed LCD DL33317: External Breast Prostheses — DME MAC2026-07-23
- Proposed LCD DL33797: Oxygen and Oxygen Equipment — DME MAC2026-07-23
- CMS Transmittal R13873OTN: Implementation of VMS Application Programming Interfaces (APIs) to Support the Durable Medical…2026-07-17
- LCD L33823: Cervical Traction Devices — DME MAC2026-07-13
- LCD L33825: Infrared Heating Pad Systems — DME MAC2026-07-13
- LCD L33690: Automatic External Defibrillators — DME MAC2026-07-13
- LCD L33733: Canes and Crutches — DME MAC2026-07-13
- LCD L33735: Cold Therapy — DME MAC2026-07-13
- LCD L33736: Commodes — DME MAC2026-07-13
- LCD L34824: Vacuum Erection Devices (VED) — DME MAC2026-07-13
- LCD L33795: Mechanical In-exsufflation Devices — DME MAC2026-07-13
- LCD L33820: Hospital Beds And Accessories — DME MAC2026-07-13
- LCD L33737: Eye Prostheses — DME MAC2026-07-13
- LCD L33738: Facial Prostheses — DME MAC2026-07-13
- LCD L33641: Orthopedic Footwear — DME MAC2026-07-13
- LCD L33799: Patient Lifts — DME MAC2026-07-13
- LCD L33784: Heating Pads and Heat Lamps — DME MAC2026-07-13
- LCD L33786: Intrapulmonary Percussive Ventilation System — DME MAC2026-07-13
- LCD L33791: Walkers — DME MAC2026-07-13
- LCD L33788: Manual Wheelchair Bases — DME MAC2026-07-13
- LCD L34823: Tumor Treatment Field Therapy (TTFT) — DME MAC2026-07-13
- LCD L34821: Transcutaneous Electrical Joint Stimulation Devices (TEJSD) — DME MAC2026-07-13
- LCD L33790: Spinal Orthoses: TLSO and LSO — DME MAC2026-07-13
- LCD L33369: Therapeutic Shoes for Persons with Diabetes — DME MAC2026-07-13
- LCD L33793: Refractive Lenses — DME MAC2026-07-13
- LCD L33692: Pressure Reducing Support Surfaces - Group 3 — DME MAC2026-07-13
- LCD L33830: Pressure Reducing Support Surfaces - Group 1 — DME MAC2026-07-13
- LCD L33642: Pressure Reducing Support Surfaces - Group 2 — DME MAC2026-07-13
- LCD L33611: Oral Appliances for Obstructive Sleep Apnea — DME MAC2026-07-13
- LCD L33785: High Frequency Chest Wall Oscillation Devices — DME MAC2026-07-13
- LCD L33797: Oxygen and Oxygen Equipment — DME MAC2026-07-13
- LCD L33801: Seat Lift Mechanisms — DME MAC2026-07-13
- LCD L38955: Enteral Nutrition — DME MAC2026-07-13
- LCD L33718: Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea — DME MAC2026-07-13
- LCD L33821: Negative Pressure Wound Therapy Pumps — DME MAC2026-07-13
- LCD L33796: Osteogenesis Stimulators — DME MAC2026-07-13
- LCD L38953: Parenteral Nutrition — DME MAC2026-07-13
- LCD L33612: Suction Pumps — DME MAC2026-07-13
- LCD L33802: Transcutaneous Electrical Nerve Stimulators (TENS) — DME MAC2026-07-13
- LCD L33828: Ostomy Supplies — DME MAC2026-07-13
- LCD L33831: Surgical Dressings — DME MAC2026-07-13
- LCD L39591: External Upper Limb Tremor Stimulator Therapy — DME MAC2026-07-13
- LCD L33822: Glucose Monitors — DME MAC2026-07-13
- LCD L33317: External Breast Prostheses — DME MAC2026-07-13
- LCD L33312: Wheelchair Seating — DME MAC2026-07-13
- LCD L33800: Respiratory Assist Devices — DME MAC2026-07-13
- LCD L33739: Speech Generating Devices (SGD) — DME MAC2026-07-13
- LCD L33789: Power Mobility Devices — DME MAC2026-07-13
- LCD L33792: Wheelchair Options/Accessories — DME MAC2026-07-13
- LCD L33318: Knee Orthoses — DME MAC2026-07-13
- LCD L33824: Immunosuppressive Drugs — DME MAC2026-07-13
- LCD L33827: Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics) — DME MAC2026-07-13
- LCD L33370: Nebulizers — DME MAC2026-07-13
- LCD L33803: Urological Supplies — DME MAC2026-07-13
- LCD L33686: Ankle-Foot/Knee-Ankle-Foot Orthosis — DME MAC2026-07-13
- LCD L33787: Lower Limb Prostheses — DME MAC2026-07-13
- LCD L36267: Bowel Management Devices — DME MAC2026-07-13
- LCD L33832: Tracheostomy Care Supplies — DME MAC2026-07-13
- LCD L33794: External Infusion Pumps — DME MAC2026-07-13
- LCD L33610: Intravenous Immune Globulin — DME MAC2026-07-13
- CMS Transmittal R13846CP: July Quarterly Update for 2026 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (…2026-07-02
- CMS Transmittal R13805CP: July Quarterly Update for 2026 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (…2026-06-19
- Proposed LCD DL33794: External Infusion Pumps — CGS2026-06-05
- Proposed LCD DL33789: Power Mobility Devices — CGS2026-06-05
- Proposed LCD DL33792: Wheelchair Options/Accessories — CGS2026-06-05
- 2026 DMEPOS Fee Schedule2026-06-02
- Contract Award for DME MAC Jurisdiction B2026-06-02
- Contract Award for DME MAC Jurisdiction A2026-06-02
- Contract Award for DME MAC Jurisdiction C (posted 8/20/2020)2026-06-02
- Contract Award for DME MAC Jurisdiction D2026-06-02
- Contract Award for DME MAC Jurisdiction C (posted 8/20/2020)2026-05-31
- Contract Award for DME MAC Jurisdiction B2026-05-31
- Contract Award for DME MAC Jurisdiction A2026-05-31
- Contract Award for DME MAC Jurisdiction D2026-05-31
Neurology62
- FDA Approval: IMAAVY (NIPOCALIMAB-AAHU) — Type 1 - New Molecular Entity2026-08-28
- FDA Approval: DULOXETINE (DULOXETINE) — Type 5 - New Formulation or New Manufacturer2026-08-21
- FDA Approval: ZAVZPRET (ZAVEGEPANT) — Type 1 - New Molecular Entity2026-08-20
- FDA Approval: ORZEYFUL (OVEPOREXTON) — Type 1 - New Molecular Entity2026-08-08
- FDA Approval: MEZOFY (ARIPIPRAZOLE) — Type 3 - New Dosage Form2026-08-06
- LCD L37761: Magnetic Resonance Image Guided High Intensity Focused Ultrasound (MRgFUS) for Essential Tremor — Palmetto GBA2026-08-06
- FDA Approval: NEURACEQ (FLORBETABEN F 18) — Type 1 - New Molecular Entity2026-07-29
- FDA Approval: TYRUKO (NATALIZUMAB-SZTN) — Type 2 - New Active Ingredient2026-07-29
- FDA Approval: SIMTRIYO (CENTANAFADINE) — Type 1 - New Molecular Entity2026-07-29
- LCD L36236: Autonomic Function Testing — Wellpoint Federal2026-07-24
- LCD L38387: Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea — Wellpoint Federal2026-07-24
- FDA Approval: SUBVENITE (LAMOTRIGINE) — Type 3 - New Dosage Form2026-07-23
- LCD L33399: EEG – Ambulatory Monitoring — Wellpoint Federal2026-07-23
- LCD L35098: Nerve Conduction Studies and Electromyography — Wellpoint Federal2026-07-23
- LCD L35028: Venous Angioplasty with or without Stent Placement for the Treatment of Chronic Cerebrospinal Venous Insufficiency — Wellpoint Federal2026-07-23
- FDA Approval: TEGRETOL (CARBAMAZEPINE) — Type 3 - New Dosage Form2026-07-18
- FDA Approval: TEGRETOL XR (CARBAMAZEPINE) — Type 3 - New Dosage Form2026-07-18
- FDA Approval: TEGRETOL (CARBAMAZEPINE) — Type 1 - New Molecular Entity2026-07-18
- FDA Approval: XELSTRYM (DEXTROAMPHETAMINE) — Type 3 - New Dosage Form2026-07-15
- FDA Approval: INBRIJA (LEVODOPA) — Type 3 - New Dosage Form2026-07-11
- FDA Approval: TASCENSO ODT (FINGOLIMOD LAURYL SULFATE) — Type 2 - New Active Ingredient2026-07-08
- FDA Approval: STRATTERA (ATOMOXETINE HYDROCHLORIDE) — Type 1 - New Molecular Entity2026-07-08
- FDA Approval: BROMOCRIPTINE MESYLATE (BROMOCRIPTINE MESYLATE) — Type 1 - New Molecular Entity2026-07-08
- FDA Approval: MAYZENT (SIPONIMOD) — Type 1 - New Molecular Entity2026-07-08
- FDA Approval: ONAPGO (APOMORPHINE HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer2026-07-08
- FDA Approval: XEOMIN (INCOBOTULINUMTOXINA) — Type 1 - New Molecular Entity2026-07-01
- FDA Approval: ENSPRYNG (SATRALIZUMAB) — Type 1 - New Molecular Entity2026-06-18
- FDA Approval: EMGALITY (GALCANEZUMAB-GNLM) — Type 1 - New Molecular Entity2026-06-10
- FDA Approval: VYEPTI (EPTINEZUMAB-JJMR) — Type 1 - New Molecular Entity2026-06-10
- FDA Approval: EPIDIOLEX (CANNABIDIOL) — Type 1 - New Molecular Entity2026-06-10
- FDA Approval: AJOVY (FREMANEZUMAB-VFRM) — Type 1 - New Molecular Entity2026-06-10
- Proposed LCD DL40224: Automated Detection and Quantification of Brain MRIs — CGS2026-06-05
- Proposed LCD DL37421: Magnetic Resonance Image Guided High Intensity Focused Ultrasound (MRgFUS) for Tremor — NGS2026-06-05
- Proposed LCD DL33398: Transcranial Magnetic Stimulation — NGS2026-06-05
- LCD L39987: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis — WPS2026-06-05
- LCD L33398: Transcranial Magnetic Stimulation — NGS2026-06-05
- LCD L36485: MolDX: HLA-DQB1*06:02 Testing for Narcolepsy — CGS2026-06-05
- LCD L37086: Transcranial Magnetic Stimulation (TMS) — Noridian2026-06-05
- LCD L37088: Transcranial Magnetic Stimulation (TMS) — Noridian2026-06-05
- LCD L34624: Somatosensory Testing — WPS2026-06-05
- LCD L37790: Magnetic Resonance Guided Focused Ultrasound Surgery System (MRgFUS) for the treatment of neurologic conditions — CGS2026-06-05
- LCD L37729: Magnetic-Resonance-Guided Focused Ultrasound Surgery (MRgFUS) for Essential Tremor and Tremor Dominant Parkinson's Disease — Noridian2026-06-05
- LCD L36861: Polysomnography and Other Sleep Studies — Noridian2026-06-05
- LCD L38700: Computed Tomography Cerebral Perfusion Analysis (CTP) — Noridian2026-06-05
- LCD L37738: Magnetic-Resonance-Guided Focused Ultrasound Surgery (MRgFUS) for Essential Tremor and Tremor Dominant Parkinson's Disease — Noridian2026-06-05
- LCD L34040: Polysomnography and Other Sleep Studies — Noridian2026-06-05
- LCD L36524: Nerve Conduction Studies and Electromyography — Noridian2026-06-05
- LCD L35124: Autonomic Function Testing — WPS2026-06-05
- LCD L36526: Nerve Conduction Studies and Electromyography — Noridian2026-06-05
- LCD L40224: Automated Detection and Quantification of Brain MRIs — CGS2026-06-05
- LCD L34623: Intraoperative Neurophysiological Testing — WPS2026-06-05
- LCD L37421: Magnetic Resonance Image Guided High Intensity Focused Ultrasound (MRgFUS) for Tremor — NGS2026-06-05
- LCD L36551: MolDX: HLA-DQB1*06:02 Testing for Narcolepsy — Noridian2026-06-05
- LCD L36544: MolDX: HLA-DQB1*06:02 Testing for Narcolepsy — Noridian2026-06-05
- LCD L35753: Non-Invasive Cerebrovascular Studies — WPS2026-06-05
- LCD L36902: Polysomnography and Other Sleep Studies — CGS2026-06-05
- LCD L38307: Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea — CGS2026-06-05
- LCD L34074: Immune Globulin Intravenous (IVIg) — Noridian2026-06-05
- LCD L34641: Transcranial Magnetic Stimulation (TMS) — WPS2026-06-05
- LCD L38528: Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea — WPS2026-06-05
- LCD L35906: Somatosensory Testing — CGS2026-06-05
- LCD L35897: Nerve Conduction Studies and Electromyography — CGS2026-06-05
Endocrinology52
- FDA Approval: MOUNJARO (TIRZEPATIDE) — Type 1 - New Molecular Entity2026-09-03
- FDA Approval: ZEPBOUND (TIRZEPATIDE) — Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated2026-08-28
- FDA Approval: SYNJARDY (EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE) — Type 4 - New Combination2026-08-14
- FDA Approval: KAZANO (ALOGLIPTIN AND METFORMIN HYDROCHLORIDE) — Type 4 - New Combination2026-08-14
- FDA Approval: SEGLUROMET (ERTUGLIFLOZIN AND METFORMIN HYDROCHLORIDE) — Type 4 - New Combination2026-08-14
- FDA Approval: JENTADUETO XR (LINAGLIPTIN AND METFORMIN HYDROCHLORIDE) — Type 4 - New Combination2026-08-14
- FDA Approval: JANUMET XR (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE) — Type 3 - New Dosage Form2026-08-14
- FDA Approval: FORTAMET (METFORMIN HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer2026-08-14
- FDA Approval: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE) — Type 4 - New Combination2026-08-14
- FDA Approval: SYNJARDY XR (EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE) — Type 3 - New Dosage Form2026-08-14
- FDA Approval: ACTOPLUS MET (PIOGLITAZONE AND METFORMIN HYDROCHLORIDE) — Type 4 - New Combination2026-08-14
- FDA Approval: INVOKAMET (CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE) — Type 4 - New Combination2026-08-14
- FDA Approval: INVOKAMET XR (CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE) — Type 4 - New Combination2026-08-14
- FDA Approval: KOMBIGLYZE XR (METFORMIN HYDROCHLORIDE) — Type 4 - New Combination2026-08-14
- FDA Approval: ZITUVIMET XR (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer2026-08-14
- FDA Approval: ZITUVIMET (METFORMIN HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer2026-08-14
- FDA Approval: METFORMIN HYDROCHLORIDE (METFORMIN HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer2026-08-14
- FDA Approval: TRIJARDY XR (EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE) — Type 4 - New Combination2026-08-14
- FDA Approval: JENTADUETO (LINAGLIPTIN AND METFORMIN HYDROCHLORIDE) — Type 4 - New Combination2026-08-14
- FDA Approval: RIOMET ER (METFORMIN HYDROCHLORIDE) — Type 3 - New Dosage Form2026-08-14
- FDA Approval: JANUMET (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE) — Type 4 - New Combination2026-08-14
- FDA Approval: TERIPARATIDE (TERIPARATIDE) — Type 5 - New Formulation or New Manufacturer2026-08-06
- FDA Approval: TERIPARATIDE (TERIPARATIDE) — Type 3 - New Dosage Form2026-08-06
- FDA Approval: TERIPARATIDE (TERIPARATIDE) — Type 5 - New Formulation or New Manufacturer2026-08-06
- FDA Approval: TYMLOS (ABALOPARATIDE) — Type 1 - New Molecular Entity2026-08-06
- FDA Approval: YORVIPATH (PALOPEGTERIPARATIDE) — Type 1 - New Molecular Entity2026-08-06
- FDA Approval: FOUNDAYO (ORFORGLIPRON) — Type 1 - New Molecular Entity2026-08-06
- FDA Approval: MACRILEN (MACIMORELIN ACETATE) — Type 1 - New Molecular Entity2026-07-29
- FDA Approval: PHEBURANE (SODIUM PHENYLBUTYRATE) — Type 5 - New Formulation or New Manufacturer2026-07-23
- LCD L38968: Thyroid Nodule Molecular Testing — Wellpoint Federal2026-07-23
- FDA Approval: PROGESTERONE (PROGESTERONE) — Type 3 - New Dosage Form2026-07-18
- FDA Approval: LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM ANHYDROUS) — Type 7 - Drug Already Marketed without Approved NDA2026-07-10
- FDA Approval: PHENTERMINE AND TOPIRAMATE (PHENTERMINE AND TOPIRAMATE) — Type 4 - New Combination2026-07-08
- Federal Register Final Rule: Medicare Program; Extending the Medicare Diabetes Prevention Program's (MDPP) Expanded Model Emergency Policy Through CY 20232026-06-05
- LCD L33431: HbA1c — Palmetto GBA2026-06-05
- LCD L38686: Implantable Continuous Glucose Monitors (I-CGM) — WPS2026-06-05
- LCD L36864: GlycoMark® Testing for Glycemic Control — Noridian2026-06-05
- LCD L36846: Measurement of Salivary Hormones — Noridian2026-06-05
- LCD L36538: Treatment of Males with Low Testosterone — Noridian2026-06-05
- LCD L38657: Implantable Continuous Glucose Monitors (I-CGM) — Noridian2026-06-05
- LCD L36569: Treatment of Males with Low Testosterone — Noridian2026-06-05
- LCD L36866: GlycoMark® Testing for Glycemic Control — Noridian2026-06-05
- LCD L36857: Measurement of Salivary Hormones — Noridian2026-06-05
- LCD L38659: Implantable Continuous Glucose Monitors (I-CGM) — Noridian2026-06-05
- LCD L38662: Implantable Continuous Glucose Monitors (I-CGM) — CGS2026-06-05
- LCD L39682: MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules — Noridian2026-06-05
- LCD L39684: MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules — Noridian2026-06-05
- LCD L38623: Implantable Continuous Glucose Monitors (I-CGM) — NGS2026-06-05
- LCD L36906: GlycoMark® Testing for Glycemic Control — CGS2026-06-05
- LCD L39720: MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules — WPS2026-06-05
- FDA Approval: NEXPLANON (ETONOGESTREL) — Type 3 - New Dosage Form2026-06-05
- FDA Approval: AFREZZA (INSULIN HUMAN) — Type 5 - New Formulation or New Manufacturer2026-06-05
Hematology52
- FDA Approval: MIMRYLO (RUSFERTIDE ACETATE) — Type 1 - New Molecular Entity2026-09-03
- FDA Approval: EMPAVELI (PEGCETACOPLAN) — Type 1 - New Molecular Entity2026-08-26
- FDA Approval: ZENBEXUS (IBERDOMIDE) — Type 1 - New Molecular Entity2026-08-19
- FDA Approval: INJECTAFER (FERRIC CARBOXYMALTOSE INJECTION) — Type 5 - New Formulation or New Manufacturer2026-08-19
- FDA Approval: ARGATROBAN (ARGATROBAN) — Type 5 - New Formulation or New Manufacturer2026-08-06
- FDA Approval: LYNOZYFIC (LINVOSELTAMAB-GCPT) — Type 1 - New Molecular Entity2026-08-05
- FDA Approval: REVLIMID (LENALIDOMIDE) — Type 1 - New Molecular Entity2026-07-25
- FDA Approval: VONJO (PACRITINIB) — Type 1 - New Molecular Entity2026-07-24
- FDA Approval: JAKAFI (RUXOLITINIB) — Type 1 - New Molecular Entity2026-07-24
- FDA Approval: OJJAARA (MOMELOTINIB) — Type 1 - New Molecular Entity2026-07-24
- FDA Approval: JAKAFI XR (RUXOLITINIB) — Type 5 - New Formulation or New Manufacturer2026-07-24
- FDA Approval: INREBIC (FEDRATINIB HYDROCHLORIDE) — Type 1 - New Molecular Entity2026-07-24
- FDA Approval: FABHALTA (IPTACOPAN) — Type 1 - New Molecular Entity2026-07-23
- FDA Approval: STIMATE (DESMOPRESSIN ACETATE) — Type 3 - New Dosage Form2026-07-18
- FDA Approval: ARGATROBAN (ARGATROBAN) — Type 5 - New Formulation or New Manufacturer2026-07-16
- FDA Approval: SARCLISA ESCENA (ISATUXIMAB-IRFC) — Type 3 - New Dosage Form2026-07-15
- FDA Approval: BKEMV (ECULIZUMAB-AEEB) — Type 2 - New Active Ingredient2026-07-08
- FDA Approval: ARGATROBAN IN 0.9% SODIUM CHLORIDE (ARGATROBAN) — Type 5 - New Formulation or New Manufacturer2026-07-01
- FDA Approval: SARCLISA (ISATUXIMAB) — Type 1 - New Molecular Entity2026-07-01
- FDA Approval: BESREMI (ROPEGINTERFERON ALFA-2B) — Type 1 - New Molecular Entity2026-07-01
- FDA Approval: ARGATROBAN (ARGATROBAN) — Type 5 - New Formulation or New Manufacturer2026-06-13
- FDA Approval: ARGATROBAN IN DEXTROSE (ARGATROBAN) — Type 5 - New Formulation or New Manufacturer2026-06-09
- Proposed LCD DL39923: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian2026-06-05
- Proposed LCD DL40000: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — CGS2026-06-05
- Proposed LCD DL40022: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — WPS2026-06-05
- Proposed LCD DL40238: MolDX: Genetic Testing for Hereditary Thrombophilia — Palmetto GBA2026-06-05
- Proposed LCD DL40259: MolDX: Genetic Testing for Hereditary Thrombophilia — CGS2026-06-05
- Proposed LCD DL40242: MolDX: Genetic Testing for Hereditary Thrombophilia — Noridian2026-06-05
- Proposed LCD DL40274: MolDX: Genetic Testing for Hereditary Thrombophilia — WPS2026-06-05
- Proposed LCD DL40334: Erythropoiesis Stimulating Agents — NGS2026-06-05
- LCD L40000: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — CGS2026-06-05
- LCD L39919: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Palmetto GBA2026-06-05
- LCD L40022: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — WPS2026-06-05
- LCD L36400: MolDX: Genetic Testing for Hypercoagulability/Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) — WPS2026-06-05
- LCD L36186: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — Noridian2026-06-05
- LCD L36180: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — Noridian2026-06-05
- LCD L36117: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — CGS2026-06-05
- LCD L36044: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — Palmetto GBA2026-06-05
- LCD L36815: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — WPS2026-06-05
- LCD L36155: MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) — Noridian2026-06-05
- LCD L36159: MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) — Noridian2026-06-05
- LCD L39923: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian2026-06-05
- LCD L39927: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian2026-06-05
- LCD L39396: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin — Noridian2026-06-05
- LCD L34314: Immune Globulin Intravenous (IVIg) — Noridian2026-06-05
- LCD L39434: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin — CGS2026-06-05
- LCD L34356: Erythropoiesis Stimulating Agents (ESA) — CGS2026-06-05
- LCD L39398: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin — Noridian2026-06-05
- LCD L38268: Immune Thrombocytopenia (ITP) Therapy — CGS2026-06-05
- LCD L35891: Intravenous Immune Globulin — CGS2026-06-05
- FDA Approval: ULTOMIRIS (RAVULIZUMAB) — Type 1 - New Molecular Entity2026-06-05
- FDA Approval: SOLIRIS (ECULIZUMAB) — Type 1 - New Molecular Entity2026-06-05
Dermatology50
- LCD L33563: Incision and Drainage (I & D) of Abscess of Skin, Subcutaneous and Accessory Structures — Wellpoint Federal2026-07-24
- FDA Approval: DUPIXENT (DUPILUMAB) — Type 1 - New Molecular Entity2026-07-23
- FDA Approval: ILUMYA (TILDRAKIZUMAB-ASMN) — Type 1 - New Molecular Entity2026-07-23
- FDA Approval: USTEKINUMAB (USTEKINUMAB) — Type 1 - New Molecular Entity2026-07-18
- FDA Approval: ELOCON (MOMETASONE FUROATE) — Type 3 - New Dosage Form2026-07-10
- FDA Approval: ELOCON (MOMETASONE FUROATE) — Type 3 - New Dosage Form2026-07-10
- FDA Approval: ELOCON (MOMETASONE FUROATE) — Type 1 - New Molecular Entity2026-07-10
- FDA Approval: ZORYVE (ROFLUMILAST) — Type 3 - New Dosage Form2026-07-08
- FDA Approval: ANZUPGO (DELGOCITINIB) — Type 1 - New Molecular Entity2026-07-08
- FDA Approval: CIBINQO (ABROCITINIB) — Type 1 - New Molecular Entity2026-07-08
- FDA Approval: LITFULO (RITLECITINIB) — Type 1 - New Molecular Entity2026-07-08
- FDA Approval: SOTYKTU (DEUCRAVACITINIB) — Type 1 - New Molecular Entity2026-07-08
- FDA Approval: LEQSELVI (DEURUXOLITINIB PHOSPHATE) — Type 1 - New Molecular Entity2026-07-08
- FDA Approval: OPZELURA (RUXOLITINIB) — Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated2026-07-08
- FDA Approval: SKYRIZI (RISANKIZUMAB-RZAA) — Type 3 - New Dosage Form2026-06-18
- FDA Approval: SKYRIZI (RISANKIZUMAB-RZAA) — Type 1 - New Molecular Entity2026-06-18
- FDA Approval: ZYRTEC HIVES (CETIRIZINE HYDROCHLORIDE) — Type 1 - New Molecular Entity2026-06-17
- FDA Approval: ABSORICA (ISOTRETINOIN) — Type 3 - New Dosage Form2026-06-17
- FDA Approval: EBGLYSS (LEBRIKIZUMAB-LBKZ) — Type 1 - New Molecular Entity2026-06-13
- Proposed LCD DL40176: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) — Noridian2026-06-05
- Proposed LCD DL40189: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) — Palmetto GBA2026-06-05
- Proposed LCD DL40168: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) — NGS2026-06-05
- Proposed LCD DL40179: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) — CGS2026-06-05
- Proposed LCD DL40193: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) — WPS2026-06-05
- LCD L37725: MolDX: Melanoma Risk Stratification Molecular Testing — Palmetto GBA2026-06-05
- LCD L38016: MolDX: Melanoma Risk Stratification Molecular Testing — CGS2026-06-05
- LCD L34200: Removal of Benign Skin Lesions — CGS2026-06-05
- LCD L38904: Wound and Ulcer Care — Noridian2026-06-05
- LCD L35163: Plastic Surgery — Noridian2026-06-05
- LCD L35702: Mohs Micrographic Surgery — Noridian2026-06-05
- LCD L34233: Benign Skin Lesion Removal (Excludes Actinic Keratosis, and Mohs) — Noridian2026-06-05
- LCD L37020: Plastic Surgery — Noridian2026-06-05
- LCD L33445: Removal of Benign and Malignant Skin Lesions — Palmetto GBA2026-06-05
- LCD L35498: Removal of Benign Skin Lesions — WPS2026-06-05
- LCD L35704: Mohs Micrographic Surgery — Noridian2026-06-05
- LCD L33979: Benign Skin Lesion Removal (Excludes Actinic Keratosis, and Mohs) — Noridian2026-06-05
- LCD L39589: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma — Noridian2026-06-05
- LCD L39373: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma — Noridian2026-06-05
- LCD L39594: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma — Noridian2026-06-05
- LCD L38151: MolDX: Pigmented Lesion Assay — Noridian2026-06-05
- LCD L38153: MolDX: Pigmented Lesion Assay — Noridian2026-06-05
- LCD L40176: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) — Noridian2026-06-05
- LCD L40189: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) — Palmetto GBA2026-06-05
- LCD L40168: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) — NGS2026-06-05
- LCD L40193: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) — WPS2026-06-05
- LCD L40179: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) — CGS2026-06-05
- LCD L38178: MolDX: Pigmented Lesion Assay — WPS2026-06-05
- LCD L34195: Mohs Micrographic Surgery — CGS2026-06-05
- LCD L39506: Cosmetic and Reconstructive Surgery — CGS Administrators2026-06-05
- FDA Approval: TREMFYA (GUSELKUMAB) — Type 1 - New Molecular Entity2026-06-05
Ophthalmology45
- LCD L34393: Ocular Photography - External — CGS2026-09-03
- LCD L39907: Micro-Invasive Glaucoma Surgery (MIGS) — WPS2026-08-27
- FDA Approval: DIFLUPREDNATE OPHTHALMIC (DIFLUPREDNATE OPHTHALMIC) — Type 1 - New Molecular Entity2026-08-15
- LCD L37244: Micro-Invasive Glaucoma Surgery (MIGS) — Wellpoint Federal2026-08-13
- LCD L39905: Cataract Surgery — WPS2026-07-30
- LCD L33558: Cataract Extraction — Wellpoint Federal2026-07-24
- LCD L33630: Corneal Pachymetry — Wellpoint Federal2026-07-23
- LCD L38014: Corneal Hysteresis — Wellpoint Federal2026-07-23
- LCD L33567: Ophthalmology: Posterior Segment Imaging (Extended Ophthalmoscopy and Fundus Photography) — Wellpoint Federal2026-07-23
- LCD L33621: Ophthalmic Biometry for Intraocular Lens Power Calculation — Wellpoint Federal2026-07-23
- LCD L33628: Panretinal (Scatter) Laser Photocoagulation — Wellpoint Federal2026-07-23
- LCD L34380: Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) — Wellpoint Federal2026-07-23
- LCD L33574: Visual Fields Testing — Wellpoint Federal2026-07-23
- LCD L36831: Visual Electrophysiology Testing — Wellpoint Federal2026-07-23
- FDA Approval: LUMVOA (VELIGROTUG-VVZE) — Type 1 - New Molecular Entity2026-07-02
- FDA Approval: FLUORESCITE (FLUORESCEIN SODIUM) — Type 5 - New Formulation or New Manufacturer2026-06-13
- FDA Approval: RANLUSPEC (RANIBIZUMAB-HKDZ) — Type 2 - New Active Ingredient2026-06-06
- LCD L34760: Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) — WPS2026-06-05
- LCD L38026: Corneal Hysteresis — Palmetto GBA2026-06-05
- LCD L34061: Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) — CGS2026-06-05
- LCD L37015: Visual Electrophysiology Testing — WPS2026-06-05
- LCD L34203: Cataract Surgery in Adults — Noridian2026-06-05
- LCD L37027: Cataract Surgery in Adults — Noridian2026-06-05
- LCD L34394: Visual Fields Testing — CGS2026-06-05
- LCD L34194: Blepharoplasty, Eyelid Surgery, and Brow Lift — Noridian2026-06-05
- LCD L38299: Micro-Invasive Glaucoma Surgery (MIGS) — Noridian2026-06-05
- LCD L36286: Blepharoplasty, Eyelid Surgery, and Brow Lift — Noridian2026-06-05
- LCD L38301: Micro-Invasive Glaucoma Surgery (MIGS) — Noridian2026-06-05
- LCD L33946: Capsule Opacification Following Cataract Surgery: Discission and YAG Laser Capsulotomy — CGS2026-06-05
- LCD L33944: Blepharoplasty — CGS2026-06-05
- LCD L34528: Blepharoplasty, Blepharoptosis and Brow Lift — WPS2026-06-05
- LCD L34008: Computerized Corneal Topography — CGS2026-06-05
- LCD L33999: Corneal Pachymetry — CGS2026-06-05
- LCD L37578: Micro-Invasive Glaucoma Surgery (MIGS) — CGS2026-06-05
- LCD L34064: Panretinal (Scatter) Laser Photocoagulation — CGS2026-06-05
- Proposed LCD DL40359: Anterior Segment Intraocular Nonbiodegradable Drug-eluting System — Noridian2026-06-05
- Proposed LCD DL40363: Anterior segment intraocular nonbiodegradable drug-eluting system — NGS2026-06-05
- Proposed LCD DL40367: Anterior segment intraocular nonbiodegradable drug-eluting system — Palmetto GBA2026-06-05
- Proposed LCD DL40356: Anterior segment intraocular nonbiodegradable drug-eluting system — CGS2026-06-05
- Proposed LCD DL40385: Anterior segment intraocular nonbiodegradable drug-eluting system — WPS2026-06-05
- LCD L38211: Corneal Hysteresis — WPS2026-06-05
- LCD L34175: Ophthalmic Angiography (Fluorescein and Indocyanine Green) — CGS Administrators2026-06-05
- LCD L34171: Nasal Punctum-Nasolacrimal Duct Dilation and Probing with or without Irrigation — CGS Administrators2026-06-05
- LCD L34399: Ophthalmology: Posterior Segment Imaging (Extended Ophthalmoscopy and Fundus Photography) — CGS Administrators2026-06-05
- LCD L34181: Ophthalmic Biometry for Intraocular Lens Power Calculation — CGS Administrators2026-06-05
Infectious Disease42
- FDA Approval: SUNLENCA (LENACAPAVIR SODIUM) — Type 1 - New Molecular Entity2026-09-03
- FDA Approval: SUNLENCA (LENACAPAVIR SODIUM) — Type 1 - New Molecular Entity2026-09-03
- FDA Approval: BIXLENVO (BICTEGRAVIR/LENACAPAVIR) — Type 4 - New Combination2026-09-03
- FDA Approval: CEFAZOLIN (CEFAZOLIN SODIUM) — Type 5 - New Formulation or New Manufacturer2026-09-03
- FDA Approval: OXACILLIN (OXACILLIN) — Type 3 - New Dosage Form2026-09-03
- FDA Approval: TIVICAY PD (DOLUTEGRAVIR SODIUM) — Type 3 - New Dosage Form2026-08-28
- FDA Approval: TIVICAY (DOLUTEGRAVIR SODIUM) — Type 1 - New Molecular Entity2026-08-28
- FDA Approval: BARACLUDE (ENTECAVIR) — Type 1 - New Molecular Entity2026-08-21
- FDA Approval: VANCOMYCIN (VANCOMYCIN) — Type 5 - New Formulation or New Manufacturer2026-08-21
- FDA Approval: MEROPENEM (MEROPENEM) — Type 5 - New Formulation or New Manufacturer2026-08-14
- FDA Approval: VEKLURY (REMDESIVIR) — Type 1 - New Molecular Entity2026-08-01
- FDA Approval: KALETRA (LOPINAVIR AND RITONAVIR) — Type 3 - New Dosage Form2026-07-29
- FDA Approval: NORVIR (RITONAVIR) — Type 3 - New Dosage Form2026-07-29
- FDA Approval: NORVIR (RITONAVIR) — Type 3 - New Dosage Form2026-07-29
- FDA Approval: BREXAFEMME (IBREXAFUNGERP CITRATE) — Type 1 - New Molecular Entity2026-07-29
- FDA Approval: REZZAYO (REZAFUNGIN) — Type 1 - New Molecular Entity2026-07-23
- FDA Approval: AUGMENTIN '125' (AMOXICILLIN) — Type 3 - New Dosage Form2026-07-23
- FDA Approval: AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN AND CLAVULANATE POTASSIUM) — Type 3 - New Dosage Form2026-07-23
- FDA Approval: AUGMENTIN '200' (AMOXICILLIN) — Type 3 - New Dosage Form2026-07-23
- FDA Approval: AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN AND CLAVULANATE POTASSIUM) — Type 3 - New Dosage Form2026-07-23
- FDA Approval: AUGMENTIN ES-600 (AMOXICILLIN AND CLAVULANATE POTASSIUM) — Type 3 - New Dosage Form2026-07-23
- FDA Approval: AMOXICILLIN AND CLAVULANATE POTASSIUM (AMOXICILLIN AND CLAVULANATE POTASSIUM) — Type 3 - New Dosage Form2026-07-23
- FDA Approval: AUGMENTIN '400' (AMOXICILLIN) — Type 3 - New Dosage Form2026-07-23
- FDA Approval: SEROSTIM (SOMATROPIN) — Type 5 - New Formulation or New Manufacturer2026-07-18
- FDA Approval: ZITHROMAX (AZITHROMYCIN DIHYDRATE) — Type 3 - New Dosage Form2026-07-16
- FDA Approval: ZITHROMAX (AZITHROMYCIN DIHYDRATE) — Type 3 - New Dosage Form2026-07-16
- FDA Approval: ZITHROMAX (AZITHROMYCIN) — Type 1 - New Molecular Entity2026-07-16
- FDA Approval: ZITHROMAX (AZITHROMYCIN DIHYDRATE) — Type 3 - New Dosage Form2026-07-16
- FDA Approval: ZITHROMAX (AZITHROMYCIN DIHYDRATE) — Type 3 - New Dosage Form2026-07-16
- FDA Approval: ZITHROMAX (AZITHROMYCIN) — Type 3 - New Dosage Form2026-07-16
- FDA Approval: SPORANOX (ITRACONAZOLE) — Type 3 - New Dosage Form2026-07-11
- FDA Approval: SPORANOX (ITRACONAZOLE) — Type 1 - New Molecular Entity2026-07-11
- FDA Approval: FETROJA (CEFIDEROCOL SULFATE TOSYLATE) — Type 1 - New Molecular Entity2026-07-08
- FDA Approval: CEFEPIME (CEFEPIME) — Type 3 - New Dosage Form2026-07-01
- FDA Approval: ZEVTERA (CEFTOBIPROLE MEDOCARIL SODIUM) — Type 1 - New Molecular Entity2026-07-01
- FDA Approval: REXTOVY (NALOXONE HYDROCHLORIDE) — Type 5 - New Formulation or New Manufacturer2026-06-18
- FDA Approval: LINEZOLID (LINEZOLID) — Type 3 - New Dosage Form2026-06-13
- FDA Approval: ZYVOX (LINEZOLID) — Type 3 - New Dosage Form2026-06-13
- FDA Approval: ZYVOX (LINEZOLID) — Type 1 - New Molecular Entity2026-06-13
- FDA Approval: LINEZOLID (LINEZOLID) — Type 5 - New Formulation or New Manufacturer2026-06-13
- FDA Approval: VANCOMYCIN HYDROCHLORIDE (VANCOMYCIN HYDROCHLORIDE) — Type 3 - New Dosage Form2026-06-13
- FDA Approval: MALARONE (ATOVAQUONE AND PROGUANIL HYDROCHLORIDE) — Type 4 - New Combination2026-06-13
Inpatient (IPPS)39
- CMS Transmittal R13932OTN: A/B Medicare Administrative Contractors (MACs) Part A and the Fiscal Intermediary Shared System…2026-08-22
- CMS Transmittal R13899FM: Extending the Default Recoupment Date for Part A Cost Report Overpayments and Revision of the…2026-08-08
- CMS Transmittal R13851CP: Inpatient Rehabilitation Facility (IRF) Annual Update: Prospective Payment System (PPS) Web…2026-08-08
- CMS Transmittal R13812CP: Fiscal Year (FY) 2027 Updates for Medicare Severity Diagnosis Related Groups (MS-DRG) Subject to…2026-08-08
- Federal Register Final Rule: Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2027 Rates; Requirements for Quality Programs; Other Policy Changes; and Adoption of Updated Versions of Certain Health Information Technology Standards2026-08-04
- CMS Transmittal R505PR1: Adjusted Hourly Salary Equivalency Amount Monthly Inflation Factors For Critical Access…2026-08-01
- LCD L33624: Psychiatric Inpatient Hospitalization — Wellpoint Federal2026-07-23
- CMS Transmittal R13877OTN: Expansion of the Supplemental Security Income (SSI) Ratio on the Inpatient Provider Specific…2026-07-17
- CMS Transmittal R13813CP: Fiscal Year (FY) 2027 Annual Update to the Medicare Code Editor (MCE) and International…2026-07-10
- CMS Transmittal R13863CP: Implementation CR - Send Transplant Program Hospital Type and the New Organ Types to the Fiscal…2026-07-10
- CMS Transmittal R13854OTN: Implementation of Editing for Programs of All-Inclusive Care for the Elderly (PACE) Inpatient…2026-07-03
- CMS Transmittal R26P240i: This transmittal updates Chapter 40, Hospital and Hospital Health Care Complex Cost Report (Form…2026-07-01
- Federal Register Proposed Rule: Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2027 Rates; Requirements for Quality Programs; and Other Policy Changes; Correction2026-06-05
- Federal Register Final Rule: Medicare Program; Changes to the Fiscal Year 2025 Hospital Inpatient Prospective Payment System (IPPS) Rates Due to Court Decision2026-06-05
- Federal Register Final Rule: Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2024 Rates; Quality Programs and Medicare Promoting Interoperability Program Requirements for Eligible Hospitals and Critical Access Hospitals; Rural Emergency Hospital and Physician-Owned Hospital Requirements; and Provider and Supplier Disclosure of Ownership; and Medicare Disproporti2026-06-05
- Federal Register Notice: Medicare Program; CY 2026 Inpatient Hospital Deductible and Hospital and Extended Care Services Coinsurance Amounts2026-06-05
- Federal Register Notice: Medicare Program; CY 2025 Inpatient Hospital Deductible and Hospital and Extended Care Services Coinsurance Amounts2026-06-05
- Federal Register Notice: Medicare Program; CY 2024 Inpatient Hospital Deductible and Hospital and Extended Care Services Coinsurance Amounts2026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs and the Children's Health Insurance Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2025 Rates; Quality Programs Requirements; and Other Policy Changes; Correction2026-06-05
- Federal Register Notice: Medicare Program; Town Hall Meeting on the Fiscal Year 2027 Applications for New Technology Add-On Payments2026-06-05
- Federal Register Notice: Medicare Program; Town Hall Meeting on the Fiscal Year 2026 Applications for New Medical Services and Technologies Add-On Payments2026-06-05
- Federal Register Final Rule: Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2024 Rates; Quality Programs and Medicare Promoting Interoperability Program Requirements for Eligible Hospitals and Critical Access Hospitals; Rural Emergency Hospital and Physician-Owned Hospital Requirements; and Provider and Supplier Disclosure of Ownership; and Medicare Disproporti2026-06-05
- Federal Register Notice: Medicare Program; Town Hall Meeting on the Fiscal Year 2025 Applications for New Medical Services and Technologies Add-On Payments2026-06-05
- Federal Register Proposed Rule: Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2027 Rates; Requirements for Quality Programs; and Other Policy Changes2026-06-05
- Federal Register Final Rule: Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2026 Rates; Changes to the FY 2025 IPPS Rates Due to Court Decision; Requirements for Quality Programs; and Other Policy Changes; Health Data, Technology, and Interoperability: Electronic Prescribing, Real-Time Prescription Benefit and Electronic Prior Authorization2026-06-05
- Federal Register Proposed Rule: Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes2026-06-05
- Federal Register Final Rule: Medicare Program: Appeal Rights for Certain Changes in Patient Status2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs and the Children's Health Insurance Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2025 Rates; Quality Programs Requirements; and Other Policy Changes; Correction2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs and the Children's Health Insurance Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2025 Rates; Quality Programs Requirements; and Other Policy Changes2026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs and the Children's Health Insurance Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2025 Rates; Quality Programs Requirements; and Other Policy Changes2026-06-05
- Federal Register Proposed Rule: Medicare Program: Appeal Rights for Certain Changes in Patient Status2026-06-05
- Federal Register Final Rule: Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2024 Rates; Quality Programs and Medicare Promoting Interoperability Program Requirements for Eligible Hospitals and Critical Access Hospitals; Rural Emergency Hospital and Physician-Owned Hospital Requirements; and Provider and Supplier Disclosure of Ownership; and Medicare Disproporti2026-06-05
- Federal Register Proposed Rule: Medicare Program; Proposed Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2024 Rates; Quality Programs and Medicare Promoting Interoperability Program Requirements for Eligible Hospitals and Critical Access Hospitals; Rural Emergency Hospital and Physician-Owned Hospital Requirements; and Provider and Supplier Disclosure of Ownership2026-06-05
- Federal Register Proposed Rule: Medicaid Program; Disproportionate Share Hospital Third-Party Payer Rule2026-06-05
- Federal Register Proposed Rule: Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2027 Rates; Requirements for Quality Programs; and Other Policy Changes; Correction2026-06-05
- Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2027 Rates; Requirements for Quality Programs; and Other Policy Changes; Correction2026-06-02
- Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2027 Rates; Requirements for Quality Programs; and Other Policy Changes; Correction2026-06-02
- Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2027 Rates; Requirements for Quality Programs; and Other Policy Changes2026-06-02
- 2026 Inpatient Prospective Payment (IPPS)2026-06-02
Orthopedics34
- LCD L39911: Total Joint Arthroplasty — WPS2026-08-27
- LCD L38213: Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF) — WPS2026-07-30
- LCD L39139: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound — Wellpoint Federal2026-07-24
- LCD L36406: Minimally-invasive Surgical (MIS) Fusion of the Sacroiliac (SI) Joint — Wellpoint Federal2026-07-23
- LCD L36039: Total Joint Arthroplasty — Wellpoint Federal2026-07-23
- LCD L39128: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound — Palmetto GBA2026-07-16
- Proposed LCD DL33318: Knee Orthoses — CGS2026-06-05
- Proposed LCD DL40232: Total Joint Arthroplasty — CGS2026-06-05
- LCD L39068: Platelet Rich Plasma — Novitas2026-06-05
- LCD L39071: Platelet Rich Plasma — First Coast2026-06-05
- LCD L39770: Cervical Fusion — NGS2026-06-05
- LCD L34246: Routine Foot Care and Debridement of Nails — CGS2026-06-05
- LCD L39758: Cervical Fusion — Noridian2026-06-05
- LCD L39960: Intervertebral Disc Repair — Noridian2026-06-05
- LCD L34218: Injections - Tendon, Ligament, Ganglion Cyst, Tunnel Syndromes and Morton's Neuroma — Noridian2026-06-05
- LCD L39058: Platelet Rich Plasma Injections for Non-Wound Injections — Noridian2026-06-05
- LCD L34076: Injections - Tendon, Ligament, Ganglion Cyst, Tunnel Syndromes and Morton's Neuroma — Noridian2026-06-05
- LCD L39962: Intervertebral Disc Repair — Noridian2026-06-05
- LCD L39762: Cervical Fusion — Noridian2026-06-05
- LCD L39810: Minimally Invasive Arthrodesis of the Sacroiliac Joint (SIJ) — Noridian2026-06-05
- LCD L39812: Minimally Invasive Arthrodesis of the Sacroiliac Joint (SIJ) — Noridian2026-06-05
- LCD L39118: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound — Noridian2026-06-05
- LCD L34163: Total Hip Arthroplasty — Noridian2026-06-05
- LCD L36575: Total Knee Arthroplasty — Noridian2026-06-05
- LCD L34106: Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF) — Noridian2026-06-05
- LCD L36577: Total Knee Arthroplasty — Noridian2026-06-05
- LCD L36573: Total Hip Arthroplasty — Noridian2026-06-05
- LCD L33569: Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF) — NGS2026-06-05
- LCD L34228: Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF) — Noridian2026-06-05
- LCD L38737: Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF) — Palmetto GBA2026-06-05
- LCD L38201: Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF) — CGS2026-06-05
- LCD L36690: Wound Application of Cellular and/or Tissue Based Products (CTPs), Lower Extremities — CGS2026-06-05
- LCD L40232: Total Joint Arthroplasty — CGS2026-06-05
- LCD L39788: Cervical Fusion — WPS2026-06-05
Gastroenterology31
- FDA Approval: GATTEX (TEDUGLUTIDE) — Type 1 - New Molecular Entity2026-09-03
- LCD L34614: Colonoscopy and Sigmoidoscopy-Diagnostic — WPS2026-08-27
- FDA Approval: BARACLUDE (ENTECAVIR) — Type 3 - New Dosage Form2026-08-21
- FDA Approval: IQIRVO (ELAFIBRANOR) — Type 1 - New Molecular Entity2026-08-13
- LCD L34659: Endoscopic Treatment of GERD — WPS2026-07-30
- FDA Approval: IDKIT HP ONE (CITRIC ACID ANHYDROUS AND 13C UREA) — Type 3 - New Dosage Form2026-07-29
- FDA Approval: REZDIFFRA (RESMETIROM) — Type 1 - New Molecular Entity2026-07-29
- LCD L38571: Colon Capsule Endoscopy (CCE) — Wellpoint Federal2026-07-23
- LCD L35080: Select Minimally Invasive GERD Procedures — Wellpoint Federal2026-07-23
- FDA Approval: TERLIVAZ (TERLIPRESSIN) — Type 1 - New Molecular Entity2026-06-13
- Proposed LCD DL38571: Colon Capsule Endoscopy (CCE) — NGS2026-06-05
- Proposed LCD DL40187: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Palmetto GBA2026-06-05
- Proposed LCD DL40272: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — WPS2026-06-05
- Proposed LCD DL40199: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — CGS2026-06-05
- Proposed LCD DL40197: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Noridian2026-06-05
- LCD L34540: Stretta Procedure — CGS2026-06-05
- LCD L38824: Colon Capsule Endoscopy (CCE) — Noridian2026-06-05
- LCD L38826: Colon Capsule Endoscopy (CCE) — Noridian2026-06-05
- LCD L35486: Pelvic Floor Dysfunction: Anorectal Manometry and EMG — WPS2026-06-05
- LCD L36868: Diagnostic and Therapeutic Colonoscopy — Noridian2026-06-05
- LCD L39780: Lower Esophageal Magnetic Sphincter Augmentation — Palmetto GBA2026-06-05
- LCD L33907: Hepatic (Liver) Function Panel — First Coast2026-06-05
- LCD L39262: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia — Noridian2026-06-05
- LCD L39264: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia — Noridian2026-06-05
- LCD L37299: MolDX: Prometheus® IBD sgi Diagnostic® Policy — Noridian2026-06-05
- LCD L37313: MolDX: Prometheus® IBD sgi Diagnostic® Policy — Noridian2026-06-05
- LCD L34213: Diagnostic and Therapeutic Colonoscopy — Noridian2026-06-05
- LCD L39276: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia — CGS2026-06-05
- LCD L37352: MolDX: Prometheus IBD sgi Diagnostic® Policy — CGS2026-06-05
- LCD L34005: Colonoscopy/Sigmoidoscopy/Proctosigmoidoscopy — CGS2026-06-05
- LCD L34081: Endoscopy by Capsule — CGS2026-06-05
Hospital Outpatient (OPPS)30
- Federal Register Notice: Medicare Program; Announcement of the Advisory Panel on Hospital Outpatient Payment Meeting-August 24, 20262026-07-08
- Federal Register Proposed Rule: Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor2026-07-07
- CMS Transmittal R13844CP: July 2026 Integrated Outpatient Code Editor (I/OCE) Specifications Version 27.22026-07-02
- CMS Transmittal R13832CP: July 2026 Update of the Hospital Outpatient Prospective Payment System (OPPS)2026-06-17
- Federal Register Final Rule: Medicare Program; Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Overall Hospital Quality Star Rating; Hospital Price Transparency; and Notice of Closure of a Teaching Hospital and Opportunity To Apply for Available Slots; Correction2026-06-05
- Federal Register Notice: Medicare Program; Announcement of the Advisory Panel on Hospital Outpatient Payment Meeting-August 25, 20252026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs, Including the Hospital Inpatient Quality Reporting Program; Health and Safety Standards for Obstetrical Services in Hospitals and Critical Access Hospitals; Prior Authorization; Requests for Information; Medicaid and CHIP Continuous Eligibility; Medicaid Clinic Services Four Walls Exceptions; Individuals Currently or Form2026-06-05
- Federal Register Notice: Medicare Program; Announcement of the Advisory Panel on Hospital Outpatient Payment Meeting-August 26-27, 20242026-06-05
- Federal Register Proposed Rule: Medicare Program: Hospital Outpatient Prospective Payment System: Remedy for the 340B-Acquired Drug Payment Policy for Calendar Years 2018-2022; Extension of Comment Period2026-06-05
- Federal Register Final Rule: Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Organ Acquisition; Rural Emergency Hospitals: Payment Policies, Conditions of Participation, Provider Enrollment, Physician Self-Referral; New Service Category for Hospital Outpatient Department Prior Authorization Process; Overall Hospital Quality Star Rating; COVID-192026-06-05
- Federal Register Final Rule: Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Organ Acquisition; Rural Emergency Hospitals: Payment Policies, Conditions of Participation, Provider Enrollment, Physician Self-Referral; New Service Category for Hospital Outpatient Department Prior Authorization Process; Overall Hospital Quality Star Rating; COVID-192026-06-05
- Federal Register Proposed Rule: Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Payment for Intensive Outpatient Services in Rural Health Clinics, Federally Qualified Health Centers, and Opioid Treatment Programs; Hospital Price Transparency; Changes to Community Mental Health Centers Conditions of Participation, Proposed Changes to the Inpatient Prospective Payment System Medicare Code Editor; Rural Emergency 2026-06-05
- Federal Register Notice: Medicare Program; Announcement of the Advisory Panel on Hospital Outpatient Payment Meeting-August 21-22, 2023-and New Panel Members2026-06-05
- Federal Register Proposed Rule: Medicare Program; Hospital Outpatient Prospective Payment System: Remedy for the 340B-Acquired Drug Payment Policy for Calendar Years 2018-20222026-06-05
- Federal Register Final Rule: Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Organ Acquisition; Rural Emergency Hospitals: Payment Policies, Conditions of Participation, Provider Enrollment, Physician Self-Referral; New Service Category for Hospital Outpatient Department Prior Authorization Process; Overall Hospital Quality Star Rating; COVID-19; Correction2026-06-05
- Federal Register Final Rule: Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Payment for Intensive Outpatient Services in Hospital Outpatient Departments, Community Mental Health Centers, Rural Health Clinics, Federally Qualified Health Centers, and Opioid Treatment Programs; Hospital Price Transparency; Changes to Community Mental Health Centers Conditions of Participation, Changes to the Inpatient Prospective2026-06-05
- Federal Register Proposed Rule: Medicare Program; Ensuring Safety Through Domestic Security With Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals2026-06-05
- Federal Register Final Rule: Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Overall Hospital Quality Star Rating; Hospital Price Transparency; and Notice of Closure of a Teaching Hospital and Opportunity To Apply for Available Slots2026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Overall Hospital Quality Star Ratings; and Hospital Price Transparency2026-06-05
- Federal Register Notice: Medicare Program; Rural Community Hospital Disemonstration Program: Solicitation of Additional Participants2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs, Including the Hospital Inpatient Quality Reporting Program; Health and Safety Standards for Obstetrical Services in Hospitals and Critical Access Hospitals; Prior Authorization; Requests for Information; Medicaid and CHIP Continuous Eligibility; Medicaid Clinic Services Four Walls Exceptions; Individuals Currently or Form2026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs, Including the Hospital Inpatient Quality Reporting Program; Health and Safety Standards for Obstetrical Services in Hospitals and Critical Access Hospitals; Prior Authorization; Requests for Information; Medicaid and CHIP Continuous Eligibility; Medicaid Clinic Services Four Walls Exceptions; Individuals Currently or F2026-06-05
- Federal Register Final Rule: Medicaid Program; Disproportionate Share Hospital Third-Party Payer Rule2026-06-05
- Federal Register Final Rule: Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Payment for Intensive Outpatient Services in Hospital Outpatient Departments, Community Mental Health Centers, Rural Health Clinics, Federally Qualified Health Centers, and Opioid Treatment Programs; Hospital Price Transparency; Changes to Community Mental Health Centers Conditions of Participation, Changes to the Inpatient Prospective2026-06-05
- Federal Register Final Rule: Medicare Program; Hospital Outpatient Prospective Payment System: Remedy for the 340B-Acquired Drug Payment Policy for Calendar Years 2018-20222026-06-05
- Federal Register Proposed Rule: Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Payment for Intensive Outpatient Services in Rural Health Clinics, Federally Qualified Health Centers, and Opioid Treatment Programs; Hospital Price Transparency; Changes to Community Mental Health Centers Conditions of Participation, Proposed Changes to the Inpatient Prospective Payment System Medicare Code Editor; Rural Emergency 2026-06-05
- Federal Register Proposed Rule: Medicare Program; Hospital Outpatient Prospective Payment System: Remedy for the 340B-Acquired Drug Payment Policy for Calendar Years 2018-20222026-06-05
- Federal Register Final Rule: Medicare Program; Treatment of Medicare Part C Days in the Calculation of a Hospital's Medicare Disproportionate Patient Percentage2026-06-05
- Federal Register Proposed Rule: Medicare Program; Medicare Disproportionate Share Hospital (DSH) Payments: Counting Certain Days Associated With Section 1115 Demonstrations in the Medicaid Fraction2026-06-05
- Medicare Program; Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Overall Hospital Quality Star Rating; Hospital Price Transparency; and Notice of Closure of a Teaching Hospital and Opportunity To Apply for Available Slots; Correction2026-06-02
Radiology30
- FDA Approval: ULTRATAG RBC (KIT FOR THE PREPARATION OF TECHNETIUM TC 99M RED BLOOD CELLS) — Type 3 - New Dosage Form2026-09-03
- FDA Approval: TAUKLARIFY (FLORQUINITAU F18) — Type 1 - New Molecular Entity2026-08-19
- LCD L33585: Breast Imaging: Breast Echography (Sonography)/Breast MRI/Ductography — Wellpoint Federal2026-07-24
- LCD L38667: Computed Tomography Cerebral Perfusion Analysis (CTP) — Wellpoint Federal2026-07-23
- LCD L33619: Nonvascular Extremity Ultrasound — Wellpoint Federal2026-07-23
- LCD L33633: Magnetic Resonance Angiography (MRA) — Wellpoint Federal2026-07-23
- LCD L33578: Transrectal Ultrasound — Wellpoint Federal2026-07-23
- LCD L35076: Stereotactic Radiation Therapy: Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) — Wellpoint Federal2026-07-23
- FDA Approval: ZYOGREEN (INDOCYANINE GREEN INJECTION) — Type 3 - New Dosage Form2026-07-15
- FDA Approval: AMBELVIST (GADOQUATRANE) — Type 1 - New Molecular Entity2026-06-18
- LCD L33459: Computerized Axial Tomography (CT), Thorax — Palmetto GBA2026-06-11
- Proposed LCD DL40276: Non-invasive Arterial Duplex Ultrasound of the Upper and Lower Extremities — Novitas2026-06-05
- Proposed LCD DL40289: Non-invasive Arterial Duplex Ultrasound of the Upper and Lower Extremities — First Coast2026-06-05
- Proposed LCD DL40332: Automated Detection and Quantification of Brain MRIs — NGS2026-06-05
- Proposed LCD DL40343: Computed Tomography Cerebral Perfusion Analysis (CTP) — WPS2026-06-05
- LCD L38694: Computed Tomography Cerebral Perfusion Analysis (CTP) — CGS2026-06-05
- LCD L38709: Computed Tomography Cerebral Perfusion Analysis (CTP) — Noridian2026-06-05
- LCD L37054: BDX-XL2 — Noridian2026-06-05
- LCD L34220: Lumbar MRI — Noridian2026-06-05
- LCD L37373: MRI and CT Scans of the Head and Neck — Noridian2026-06-05
- LCD L37281: Lumbar MRI — Noridian2026-06-05
- LCD L35175: MRI and CT Scans of the Head and Neck — Noridian2026-06-05
- LCD L37547: Chest X-Ray Policy — Noridian2026-06-05
- LCD L34045: Non-Invasive Vascular Studies — CGS2026-06-05
- LCD L37549: Chest X-Ray Policy — Noridian2026-06-05
- LCD L33950: Breast Imaging Mammography/Breast Echography (Sonography)/Breast MRI/Ductography — CGS2026-06-05
- LCD L35755: Non-Invasive Abdominal / Visceral Vascular Studies — WPS2026-06-05
- LCD L39521: Positron Emission Tomography (PET) Scan for Inflammation and Infection — CGS2026-06-05
- LCD L40276: Non-invasive Arterial Duplex Ultrasound of the Upper and Lower Extremities — Novitas2026-06-05
- LCD L40289: Non-invasive Arterial Duplex Ultrasound of the Upper and Lower Extremities — First Coast2026-06-05
Medicare Advantage27
- Federal Register Notice: Medicare Program; Approved Renewal of Deeming Authority of the National Committee for Quality Assurance (NCQA) for Medicare Advantage Health Maintenance Organizations and Preferred Provider Organizations2026-07-25
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Notice: Medicare Program; Request for Information on Medicare Advantage Data2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (PACE)-Finalization of Format Provider Directories for Medicare Plan Finder2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, Program of All-Inclusive Care for the Elderly (PACE), Medicaid Fee-For-Service, and Medicaid Managed Care Programs for Years 2020 and 20212026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability Standards and Prior Authorization for Drugs for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, and Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges2026-06-05
- Federal Register Final Rule: Medicare Program; Contract Year 2027 and Certain Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program2026-06-05
- Federal Register Proposed Rule: Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program2026-06-05
- Federal Register Proposed Rule: Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model2026-06-05
- Federal Register Proposed Rule: Global Benchmark for Efficient Drug Pricing (GLOBE) Model2026-06-05
- Federal Register Proposed Rule: Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request2026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly2026-06-05
- Federal Register Final Rule: Medicare Program; Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Program for Contract Year 2024-Remaining Provisions and Contract Year 2025 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (PACE)2026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Advancing Interoperability and Improving Prior Authorization Processes for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges, Merit-Based Incentive Payment System (MIPS) Eligible Clinicians, and Eligi2026-06-05
- Federal Register Proposed Rule: Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2025; Updating Section 1332 Waiver Public Notice Procedures; Medicaid; Consumer Operated and Oriented Plan (CO-OP) Program; and Basic Health Program2026-06-05
- Federal Register Proposed Rule: Medicare Program; Contract Year 2025 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications2026-06-05
- Federal Register Final Rule: Medicare Program; Contract Year 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly2026-06-05
- Medical Devices; Hematology and Pathology Devices; Classification of the Von Willebrand Factor Assay2026-06-02
- Medicaid Program; Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Medicaid Practitioner Payments2026-06-02
- Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability Standards and Prior Authorization for Drugs for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, and Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges2026-06-02
- Managed Care2026-06-02
- Medicare Program; Contract Year 2027 and Certain Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program2026-06-02
- Request for Information (RFI) Related to Comprehensive Regulations To Uncover Suspicious Healthcare (CRUSH)2026-06-02
Urology25
- Proposed LCD DL38367: Fluid Jet System Treatment for LUTS/BPH — NGS2026-06-05
- Proposed LCD DL38378: Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH) — CGS2026-06-05
- Proposed LCD DL38682: Transurethral Waterjet Ablation of the Prostate — WPS2026-06-05
- Proposed LCD DL38705: Transurethral Waterjet Ablation of the Prostate — Noridian2026-06-05
- Proposed LCD DL38707: Transurethral Waterjet Ablation of the Prostate — Noridian2026-06-05
- Proposed LCD DL38549: Transurethral Waterjet Ablation of the Prostate — Palmetto GBA2026-06-05
- Proposed LCD DL33803: Urological Supplies — CGS2026-06-05
- LCD L38367: Fluid Jet System Treatment for LUTS/BPH — NGS2026-06-05
- LCD L34056: Urodynamics — CGS2026-06-05
- LCD L38682: Transurethral Waterjet Ablation of the Prostate — WPS2026-06-05
- LCD L38549: Transurethral Waterjet Ablation of the Prostate — Palmetto GBA2026-06-05
- LCD L39284: Prostate Cancer Detection with IsoPSA® — CGS2026-06-05
- LCD L39688: MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers — Noridian2026-06-05
- LCD L36975: Bladder/Urothelial Tumor Markers — CGS2026-06-05
- LCD L38705: Transurethral Waterjet Ablation of the Prostate — Noridian2026-06-05
- LCD L38707: Transurethral Waterjet Ablation of the Prostate — Noridian2026-06-05
- LCD L38997: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — CGS2026-06-05
- LCD L34085: Post-Void Residual Urine and/or Bladder Capacity by Ultrasound — CGS2026-06-05
- LCD L38378: Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH) — CGS2026-06-05
- LCD L34090: Laser Ablation of the Prostate — CGS2026-06-05
- LCD L38576: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer — Palmetto GBA2026-06-05
- LCD L38647: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer — Noridian2026-06-05
- LCD L38684: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer — WPS2026-06-05
- Proposed LCD DL40378: Urine-based Biomarkers in Patients with Microhematuria — Novitas2026-06-05
- Proposed LCD DL40380: Urine-based Biomarkers in Patients with Microhematuria — First Coast2026-06-05
Skilled Nursing Facility22
- Federal Register Notice: Privacy Act of 1974; System of Records2026-08-20
- CMS Transmittal R13850CP: Medicare Part A Skilled Nursing Facility (SNF) Prospective Payment System (PPS) Web Pricer…2026-08-08
- Federal Register Final Rule: Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program for Federal Fiscal Year 20272026-07-31
- CMS Transmittal R503PR1: Section 2231, Regional Medicare Swing-Bed-Rates, updates Table 38 to correct the Medicare…2026-07-02
- CMS Transmittal R530PR1: Section 2231, Regional Medicare Swing-Bed-Rates, updates Table 38 to correct the Medicare…2026-07-01
- Federal Register Final Rule: Medicare and Medicaid Programs; Repeal of Minimum Staffing Standards for Long-Term Care Facilities2026-06-05
- Federal Register Final Rule: Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program and Value-Based Purchasing Program for Federal Fiscal Year 2025; Correction2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; Minimum Staffing Standards for Long-Term Care Facilities and Medicaid Institutional Payment Transparency Reporting; Correction2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; Policy and Regulatory Changes to the Omnibus COVID-19 Health Care Staff Vaccination Requirements; Additional Policy and Regulatory Changes to the Requirements for Long-Term Care (LTC) Facilities and Intermediate Care Facilities for Individuals With Intellectual Disabilities (ICFs-IID) To Provide COVID-19 Vaccine Education and Offer Vaccinations to Residents, Clients, and Staff; Policy and Regulatory Changes to the Long Term Care Facili2026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs; Disclosures of Ownership and Additional Disclosable Parties Information for Skilled Nursing Facilities and Nursing Facilities2026-06-05
- Federal Register Proposed Rule: Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program for Federal Fiscal Year 20272026-06-05
- Federal Register Final Rule: Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program for Federal Fiscal Year 20262026-06-05
- Federal Register Proposed Rule: Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program for Federal Fiscal Year 20262026-06-05
- Federal Register Final Rule: Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program and Value-Based Purchasing Program for Federal Fiscal Year 20252026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; Minimum Staffing Standards for Long-Term Care Facilities and Medicaid Institutional Payment Transparency Reporting2026-06-05
- Federal Register Proposed Rule: Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program and Value-Based Purchasing Program for Federal Fiscal Year 20252026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; Disclosures of Ownership and Additional Disclosable Parties Information for Skilled Nursing Facilities and Nursing Facilities; Medicare Providers' and Suppliers' Disclosure of Private Equity Companies and Real Estate Investment Trusts2026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs; Minimum Staffing Standards for Long-Term Care Facilities and Medicaid Institutional Payment Transparency Reporting2026-06-05
- Federal Register Final Rule: Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program and Value-Based Purchasing Program for Federal Fiscal Year 20242026-06-05
- Federal Register Proposed Rule: Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program and Value-Based Purchasing Program for Federal Fiscal Year 20242026-06-05
- CMS Transmittal R3P249i: This transmittal updates Chapter 49, Skilled Nursing Facility and Skilled Nursing Facility…2026-06-05
- 2026 Skilled Nursing Facility PPS2026-06-02
ESRD21
- CMS Transmittal R246SOMA: Revisions to the State Operations Manual (SOM) Appendix H, End-Stage Renal Disease (ESRD)…2026-08-18
- LCD L37475: Frequency of Hemodialysis — Wellpoint Federal2026-07-23
- CMS Transmittal R13822CP: Quarterly Update to the End Stage Renal Disease Prospective Payment System (ESRDPPS)2026-06-10
- Federal Register Final Rule: Principles of Reasonable Cost Reimbursement; Payment for End-Stage Renal Disease Services; Prospectively Determined Payment Rates for Skilled Nursing Facilities; Payment for Acute Kidney Injury Dialysis2026-06-05
- Federal Register Notice: Medicare and Medicaid Programs: Application From the Accreditation Commission for Health Care, Inc. for Continued Approval of Its End-Stage Renal Disease (ESRD) Accreditation Program2026-06-05
- Federal Register Final Rule: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model2026-06-05
- Federal Register Proposed Rule: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model2026-06-05
- Federal Register Final Rule: Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model2026-06-05
- Federal Register Final Rule: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, Conditions for Coverage for End-Stage Renal Disease Facilities, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model2026-06-05
- Federal Register Proposed Rule: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, Conditions for Coverage for End-Stage Renal Disease Facilities, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model2026-06-05
- Federal Register Proposed Rule: Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model2026-06-05
- Federal Register Final Rule: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model2026-06-05
- Federal Register Proposed Rule: Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model2026-06-05
- LCD L37502: Frequency of Hemodialysis — Noridian2026-06-05
- LCD L37504: Frequency of Hemodialysis — Noridian2026-06-05
- LCD L37537: Frequency of Hemodialysis — WPS2026-06-05
- LCD L34062: Dialysis Access Maintenance — CGS2026-06-05
- LCD L37575: Frequency of Hemodialysis — CGS2026-06-05
- LCD L40334: Erythropoiesis Stimulating Agents — NGS2026-06-05
- CMS Transmittal R13770CP: Update to the End Stage Renal Disease Prospective Payment System (ESRDPPS)2026-06-05
- 2026 ESRD Prospective Payment System2026-06-02
Allergy/Immunology19
- Proposed LCD DL40050: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — Noridian2026-06-05
- Proposed LCD DL40052: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — Noridian2026-06-05
- Proposed LCD DL40048: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — NGS2026-06-05
- Proposed LCD DL39314: Off-Label Use of Intravenous Immune Globulin (IVIG) — NGS2026-06-05
- Proposed LCD DL36408: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — WPS2026-06-05
- Proposed LCD DL40330: Allergy Diagnostic Testing — NGS2026-06-05
- Proposed LCD DL40324: Allergy Diagnostic Testing — Noridian2026-06-05
- Proposed LCD DL40328: Allergy Diagnostic Testing — Palmetto GBA2026-06-05
- Proposed LCD DL40341: Allergy Diagnostic Testing — WPS2026-06-05
- Proposed LCD DL40326: Allergy Diagnostic Testing — CGS2026-06-05
- LCD L39314: Off-Label Use of Intravenous Immune Globulin (IVIG) — NGS2026-06-05
- LCD L34063: RAST Type Tests — CGS2026-06-05
- LCD L40056: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — CGS2026-06-05
- LCD L36408: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — WPS2026-06-05
- LCD L40048: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — NGS2026-06-05
- LCD L40046: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — Palmetto GBA2026-06-05
- LCD L40050: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — Noridian2026-06-05
- LCD L40052: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) — Noridian2026-06-05
- LCD L32553: Allergy Immunotherapy — CGS2026-06-05
Medicaid19
- CMS Transmittal R13945MPI: Updates to Chapter 3, Chapter 4, and Chapter 5 in Publication (Pub.) 100-15, Including Updates…2026-09-04
- Federal Register Final Rule: Medicaid Program; Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children2026-08-13
- Federal Register Proposed Rule: Medicaid Program; Amending the Indirect Hold Harmless Threshold of Health Care-Related Taxes2026-07-23
- Federal Register Notice: Medicaid and Children's Health Insurance Program (CHIP) Generic Information Collection Activities: Proposed Collection; Comment Request2026-07-16
- Federal Register Notice: Privacy Act of 1974; Matching Program2026-07-07
- Federal Register Final Rule: Streamlining Medicaid; Medicare Savings Program Eligibility Determination and Enrollment2026-06-05
- Federal Register Proposed Rule: Medicaid Program; Preserving Medicaid Funding for Vulnerable Populations-Closing a Health Care-Related Tax Loophole Proposed Rule2026-06-05
- Federal Register Final Rule: Medicaid Program; Preserving Medicaid Funding for Vulnerable Populations-Closing a Health Care-Related Tax Loophole2026-06-05
- Federal Register Final Rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program2026-06-05
- Federal Register Final Rule: Medicaid Program; Medicaid and Children's Health Insurance Program (CHIP) Managed Care Access, Finance, and Quality2026-06-05
- Federal Register Final Rule: Medicaid Program; Streamlining the Medicaid, Children's Health Insurance Program, and Basic Health Program Application, Eligibility Determination, Enrollment, and Renewal Processes2026-06-05
- Federal Register Proposed Rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program2026-06-05
- Federal Register Proposed Rule: Medicaid Program; Ensuring Access to Medicaid Services2026-06-05
- Medicare and Medicaid Programs; Organ Procurement Organizations Conditions for Coverage: Revisions to the Conditions for Coverage2026-06-02
- Medicaid Program; Preserving Medicaid Funding for Vulnerable Populations-Closing a Health Care-Related Tax Loophole2026-06-02
- Acting Inspector General Juliet T. Hodgkins Remarks on the 2025 National Health Care Fraud Takedown VideosJune 30, 20252026-06-02
- Combating Durable Medical Equipment Fraud VideosNovember 25, 20252026-06-02
- Medicaid Fraud Control Units Annual Report: Fiscal Year 2024 VideosJune 25, 20252026-06-02
- 2025 National Health Care Fraud Takedown Media MaterialsJune 30, 20252026-06-02
Outpatient19
- LCD L35001: Reduction Mammaplasty — Wellpoint Federal2026-07-23
- LCD L33396: Posterior Tibial Nerve Stimulation for Voiding Dysfunction — Wellpoint Federal2026-07-23
- LCD L33631: Outpatient Physical and Occupational Therapy Services — Wellpoint Federal2026-07-23
- LCD L33576: Urodynamics — Wellpoint Federal2026-07-23
- LCD L33636: Routine Foot Care and Debridement of Nails — Wellpoint Federal2026-07-23
- LCD L33575: Varicose Veins of the Lower Extremity, Treatment of — Wellpoint Federal2026-07-23
- Federal Register Notice: Medicare and Medicaid Programs; Application From The Joint Commission for Continued CMS Approval of Its Home Health Agency (HHA) Accreditation Program2026-07-10
- CMS Transmittal R13836CP: July 2026 Update of the Ambulatory Surgical Center (ASC) Payment System2026-06-25
- Federal Register Final Rule: Medicare Program; Updates to Face-to-Face Encounter and Written Order Prior to Delivery List2026-06-05
- Federal Register Notice: Medicare Program; Medicare Part B Monthly Actuarial Rates, Premium Rates, and Annual Deductible Beginning January 1, 20252026-06-05
- Federal Register Notice: Agency Information Collection Activities: Submission for OMB Review; Comment Request2026-06-05
- LCD L34596: Immunizations — WPS2026-06-05
- LCD L37011: ProMark® Risk Score — WPS2026-06-05
- LCD L34771: Immune Globulins — WPS2026-06-05
- LCD L35125: Wound Care — Novitas2026-06-05
- LCD L34209: Treatment of Varicose Veins of the Lower Extremities — Noridian2026-06-05
- LCD L39650: MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules — CGS Administrators2026-06-05
- LCD L34353: Outpatient Psychiatry and Psychology Services — CGS Administrators2026-06-05
- LCD L34049: Outpatient Physical and Occupational Therapy Services — CGS Administrators2026-06-05
Pulmonology19
- FDA Approval: JASCAYD (NERANDOMILAST) — Type 1 - New Molecular Entity2026-08-19
- FDA Approval: WINREVAIR (SOTATERCEPT-CSRK) — Type 1 - New Molecular Entity2026-08-15
- FDA Approval: XOLAIR (OMALIZUMAB) — Type 1 - New Molecular Entity2026-08-12
- FDA Approval: ADEMPAS (RIOCIGUAT) — Type 1 - New Molecular Entity2026-08-08
- FDA Approval: ORENITRAM (TREPROSTINIL) — Type 3 - New Dosage Form2026-08-06
- FDA Approval: ARIKAYCE (AMIKACIN) — Type 3 - New Dosage Form2026-07-01
- LCD L39711: MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy — WPS2026-06-25
- LCD L39658: MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy — CGS2026-06-18
- FDA Approval: PROVOCHOLINE (METHACHOLINE CHLORIDE) — Type 1 - New Molecular Entity2026-06-11
- Proposed LCD DL33370: Nebulizers — CGS2026-06-05
- LCD L34541: Transtelephonic Spirometry — CGS2026-06-05
- LCD L34149: Respiratory Care — Noridian2026-06-05
- LCD L37293: Respiratory Care — Noridian2026-06-05
- LCD L38310: Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea — Noridian2026-06-05
- LCD L37887: MolDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test — Noridian2026-06-05
- LCD L39678: MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy — Noridian2026-06-05
- LCD L39680: MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy — Noridian2026-06-05
- LCD L37891: MolDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test — Noridian2026-06-05
- LCD L37905: MolDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test — CGS Administrators2026-06-05
Physician Fee Schedule18
- CMS Transmittal R13929CP: Quarterly Update to the Medicare Physician Fee Schedule Database (MPFSDB) - October 2026 Update…2026-08-27
- CMS Transmittal R504PR1: Provides for calendar year (CY) inflation factors to update previous years’ reasonable…2026-08-01
- Federal Register Proposed Rule: Medicare and Medicaid Programs; CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program2026-07-16
- CMS Transmittal R13845CP: Quarterly Update to the Medicare Physician Fee Schedule Database (MPFSDB) - July 2026 Update2026-07-01
- Federal Register Final Rule: Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program; Correction2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program; Correction2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments; and Appeal Rights for Certain Changes in Patient Status; Corrections and Correcting Amendment2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Advantage; Medicare and Medicaid Provider and Supplier Enrollment Policies; and Basic Health Program; Corrections2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs, CY 2023 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Implementing Requirements for Manufacturers of Certain Single-Dose Container or Single-Use Package Drugs To Provide Refunds With Respect to Discarded Amounts; and COVID-19 Interim Final Rules; Corrections2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program2026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program; Correction2026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments2026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Advantage; Medicare and Medicaid Provider and Supplier Enrollment Policies; and Basic Health Program2026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs; CY 2024 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Advantage; Medicare and Medicaid Provider and Supplier Enrollment Policies; and Basic Health Program2026-06-05
- Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program; Correction2026-06-02
- 2026 Physician Fee Schedule (PFS)2026-06-02
Rheumatology18
- FDA Approval: USTEKINUMAB (USTEKINUMAB) — Type 3 - New Dosage Form2026-09-03
- FDA Approval: BENLYSTA (BELIMUMAB) — Type 1 - New Molecular Entity2026-08-27
- FDA Approval: BENLYSTA (BELIMUMAB) — Type 3 - New Dosage Form2026-08-27
- FDA Approval: YESINTEK (USTEKINUMAB) — Type 2 - New Active Ingredient2026-08-20
- FDA Approval: SAPHNELO (ANIFROLUMAB-FNIA) — Type 1 - New Molecular Entity2026-08-13
- FDA Approval: KRYSTEXXA (PEGLOTICASE) — Type 1 - New Molecular Entity2026-08-13
- FDA Approval: TRUTAKNA (atacicept-vymj) — Type 1 - New Molecular Entity2026-07-11
- FDA Approval: XELJANZ (TOFACITINIB) — Type 1 - New Molecular Entity2026-07-08
- FDA Approval: XELJANZ XR (TOFACITINIB) — Type 3 - New Dosage Form2026-07-08
- FDA Approval: RINVOQ (UPADACITINIB) — Type 1 - New Molecular Entity2026-07-08
- FDA Approval: XELJANZ (TOFACITINIB) — Type 3 - New Dosage Form2026-07-08
- FDA Approval: OLUMIANT (BARICITINIB) — Type 1 - New Molecular Entity2026-07-08
- FDA Approval: RINVOQ (UPADACITINIB) — Type 3 - New Dosage Form2026-07-08
- FDA Approval: EXDENSUR (DEPEMOKIMAB) — Type 1 - New Molecular Entity2026-06-13
- LCD L39427: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis — CGS2026-06-05
- LCD L39481: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis — WPS2026-06-05
- LCD L39467: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis — Noridian2026-06-05
- LCD L39469: MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis — Noridian2026-06-05
OIG Work Plan16
- Compliance Compliance Compliance Guidance Corporate Integrity Agreements Advisory Opinions Accountable Care Organizations Open Letters RAT-STATS - Statistical Software Safe Harbor Regulations Self-Disclosure Information Special Fraud Alerts, Bulletins, and Other Guidance A Roadmap for Physicians Single Audits Frequently Asked Questions (FAQs)2026-06-02
- Contract Fraud2026-06-02
- Fraud Fraud Child Support Enforcement Consumer Alerts Contract Fraud Enforcement Actions Fraud Risk and Heightened Scrutiny Fugitives Grant Fraud Medicaid Fraud Control Units Medicare Fraud Strike Force Operation CARE State False Claims Act Reviews Report Fraud, Waste, and Abuse2026-06-02
- Medicare Fraud Strike Force2026-06-02
- HHS-OIG Audit Finds Maine Made At Least $45.6 Million in Improper Medicaid Payments for Autism Services News Releases & ArticlesJanuary 22, 20262026-06-02
- Fraud Risk and Heightened Scrutiny2026-06-02
- Exclusions Exclusions LEIE Quick Tips & Instructions Online Searchable Database LEIE Database & Supplement Downloads Special Advisory Bulletin and Other Guidance Waivers About Reinstatements Working With Federal and State Partners on Health Care Exclusions Guidance for State Medicaid Agencies Frequently Asked Questions Contact the Exclusions Program2026-06-02
- Special Fraud Alerts, Bulletins, and Other Guidance2026-06-02
- Medicaid Fraud Control Units2026-06-02
- State False Claims Act Reviews2026-06-02
- Report Fraud, Waste, and Abuse2026-06-02
- Grant Fraud2026-06-02
- Single Audits2026-06-02
- Guidance for State Medicaid Agencies2026-06-02
- With about 1,600 people dedicated to combating fraud, waste, and abuse in Medicare, Medicaid, and more than 100 other HHS programs, there is a lot of government oversight going on at OIG. This section features several resources to help you keep track of all the latest developments.Recently Published Content HHS-OIG Audit Finds Maine Made At Least $45.6 Million in Improper Medicaid Payments for Autism Services News Releases & ArticlesJanuary 22, 2026 HHS-OIG Advisory Opinion Process: Five Things You Need to Know VideosJanuary 21, 2026 At a Glance: Fall 2025 Semiannual Report to Congress News Releases & ArticlesJanuary 21, 2026 Combating Durable Medical Equipment Fraud VideosNovember 25, 2025 HHS-OIG Oversight of Grants and Contracts VideosJuly 15, 2025 Acting Inspector General Juliet T. Hodgkins Remarks on the 2025 National Health Care Fraud Takedown VideosJune 30, 2025 2025 National Health Care Fraud Takedown Media MaterialsJune 30, 2025 Medicaid Fraud Control Units Annual Report: Fiscal Year 2024 VideosJune 25, 20252026-06-02
- A Roadmap for Physicians2026-06-02
Hospice15
- CMS Transmittal R13944CP: Reporting Face-to-Face Encounter Conducted by a Hospice Physician or Hospice Nurse Practitioner…2026-09-02
- CMS Transmittal R13924CP: Update to Hospice Payment Rates, Hospice Cap, Hospice Wage Index and Hospice Pricer for Fiscal…2026-08-19
- CMS Transmittal R13872CP: Update to Hospice Payment Rates, Hospice Cap, Hospice Wage Index and Hospice Pricer for Fiscal…2026-08-08
- Federal Register Final Rule: Medicare Program; FY 2027 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirements2026-08-01
- LCD L33393: Hospice - Determining Terminal Status — Wellpoint Federal2026-07-24
- CMS Transmittal R13860CP: Reporting Face-to-Face Encounter Conducted by a Hospice Physician or Hospice Nurse Practitioner…2026-07-11
- Federal Register Proposed Rule: Medicare Program; FY 2027 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirements2026-06-05
- Federal Register Final Rule: Medicare Program; FY 2026 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirements2026-06-05
- Federal Register Proposed Rule: Medicare Program; FY 2026 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirements2026-06-05
- Federal Register Final Rule: Medicare Program; FY 2025 Hospice Wage Index and Payment Rate Update, Hospice Conditions of Participation Updates, and Hospice Quality Reporting Program Requirements2026-06-05
- Federal Register Proposed Rule: Medicare Program; FY 2025 Hospice Wage Index and Payment Rate Update, Hospice Conditions of Participation Updates, and Hospice Quality Reporting Program Requirements2026-06-05
- Federal Register Final Rule: Medicare Program; FY 2024 Hospice Wage Index and Payment Rate Update, Hospice Conditions of Participation Updates, Hospice Quality Reporting Program Requirements, and Hospice Certifying Physician Provider Enrollment Requirements2026-06-05
- Federal Register Proposed Rule: Medicare Program; FY 2024 Hospice Wage Index and Payment Rate Update, Hospice Conditions of Participation Updates, Hospice Quality Reporting Program Requirements, and Hospice Certifying Physician Provider Enrollment Requirements2026-06-05
- LCD L34538: Hospice Determining Terminal Status — CGS2026-06-05
- Medicare Program; FY 2027 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirements2026-06-02
Home Health14
- CMS Transmittal R245SOMA: Revised Appendix B, Interpretive Guidelines for Home Health Agencies: New Acceptance-to-Service…2026-08-06
- CMS Transmittal R13794CP: Quarterly Update of Healthcare Common Procedure Coding System (HCPCS) Codes Used for Home Health…2026-07-10
- CMS Transmittal R13793CP: Quarterly Update to Home Health (HH) Grouper2026-07-10
- Federal Register Proposed Rule: Medicare Program; Calendar Year (CY) 2025 Home Health Prospective Payment System (HH PPS) Rate Update; HH Quality Reporting Program Requirements; HH Value-Based Purchasing Expanded Model Requirements; Home Intravenous Immune Globulin (IVIG) Items and Services Rate Update; and Other Medicare Policies2026-06-05
- Federal Register Proposed Rule: Medicare Program; Calendar Year (CY) 2024 Home Health (HH) Prospective Payment System Rate Update; HH Quality Reporting Program Requirements; HH Value-Based Purchasing Expanded Model Requirements; Home Intravenous Immune Globulin Items and Services; Hospice Informal Dispute Resolution and Special Focus Program Requirements, Certain Requirements for Durable Medical Equipment Prosthetics and Orthotics Supplies; and Provider and Supplier Enrollment Requirements2026-06-05
- Federal Register Final Rule: Medicare and Medicaid Programs; Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the HH Value-Based Purchasing Expanded Model; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates; DMEPOS Accreditation Requirements; Provider Enrollment; and Other Medicare and Medicaid Policies2026-06-05
- Federal Register Notice: Privacy Act of 1974; System of Records2026-06-05
- Federal Register Proposed Rule: Medicare and Medicaid Programs; Calendar Year 2026 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the HH Value-Based Purchasing Expanded Model; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program Updates; DMEPOS Accreditation Requirements; Provider Enrollment; and Other Medicare and Medicaid Policies2026-06-05
- Federal Register Final Rule: Medicare Program; Calendar Year (CY) 2025 Home Health Prospective Payment System (HH PPS) Rate Update; HH Quality Reporting Program Requirements; HH Value-Based Purchasing Expanded Model Requirements; Home Intravenous Immune Globulin (IVIG) Items and Services Rate Update; and Other Medicare Policies2026-06-05
- Federal Register Final Rule: Medicare Program; Calendar Year (CY) 2024 Home Health (HH) Prospective Payment System Rate Update; HH Quality Reporting Program Requirements; HH Value-Based Purchasing Expanded Model Requirements; Home Intravenous Immune Globulin Items and Services; Hospice Informal Dispute Resolution and Special Focus Program Requirements, Certain Requirements for Durable Medical Equipment Prosthetics and Orthotics Supplies; and Provider and Supplier Enrollment Requirements2026-06-05
- LCD L34562: Home Health Skilled Nursing Care-Teaching and Training: Alzheimer's Disease and Behavioral Disturbances — Palmetto GBA2026-06-05
- LCD L33942: Physical Therapy - Home Health — CGS2026-06-05
- CMS Transmittal R7P247i: This transmittal updates Chapter 47, Home Health Agency Cost Report, Form CMS-1728-20, by…2026-06-05
- 2026 Home Health Prospective Payment2026-06-02
Infectious Disease / Microbiology10
- LCD L39027: Respiratory Pathogen Panel Testing — Wellpoint Federal2026-07-24
- LCD L39044: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing — WPS2026-06-25
- LCD L38988: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing — Palmetto GBA2026-06-05
- LCD L38331: MolDX: Blood Product Molecular Antigen Typing — Noridian2026-06-05
- LCD L38333: MolDX: Blood Product Molecular Antigen Typing — Noridian2026-06-05
- LCD L39001: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing — Noridian2026-06-05
- LCD L39003: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing — Noridian2026-06-05
- LCD L39226: Multiplex Gastrointestinal Pathogen Panel (GPP) Tests for Acute Gastroenteritis (AGE) — NGS2026-06-05
- LCD L38249: MolDX: Blood Product Molecular Antigen Typing — CGS2026-06-05
- LCD L39038: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing — CGS2026-06-05
Inpatient Psychiatric (IPF)9
- Federal Register Final Rule: Medicare Program; FY 2027 Inpatient Psychiatric Facilities Prospective Payment System-Rate Update2026-07-31
- Federal Register Proposed Rule: Medicare Program; FY 2027 Inpatient Psychiatric Facilities Prospective Payment System-Rate Update2026-06-05
- Federal Register Final Rule: Medicare Program; FY 2026 Inpatient Psychiatric Facilities Prospective Payment System-Rate Update2026-06-05
- Federal Register Proposed Rule: Medicare Program; FY 2026 Inpatient Psychiatric Facilities Prospective Payment System-Rate Update2026-06-05
- Federal Register Final Rule: Medicare Program; FY 2025 Inpatient Psychiatric Facilities Prospective Payment System-Rate Update2026-06-05
- Federal Register Proposed Rule: Medicare Program; FY 2025 Inpatient Psychiatric Facilities Prospective Payment System-Rate Update2026-06-05
- Federal Register Final Rule: Medicare Program; FY 2024 Inpatient Psychiatric Facilities Prospective Payment System-Rate Update2026-06-05
- Federal Register Proposed Rule: Medicare Program; FY 2024 Inpatient Psychiatric Facilities Prospective Payment System-Rate Update2026-06-05
- Medicare Program; FY 2027 Inpatient Psychiatric Facilities Prospective Payment System-Rate Update2026-06-02
Inpatient Rehabilitation (IRF)9
- Federal Register Final Rule: Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2027 and Updates to the IRF Quality Reporting Program2026-08-01
- Federal Register Proposed Rule: Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2027 and Updates to the IRF Quality Reporting Program2026-06-05
- Federal Register Proposed Rule: Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2026 and Updates to the IRF Quality Reporting Program2026-06-05
- Federal Register Proposed Rule: Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2025 and Updates to the IRF Quality Reporting Program2026-06-05
- Federal Register Final Rule: Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2026 and Updates to the IRF Quality Reporting Program2026-06-05
- Federal Register Final Rule: Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2025 and Updates to the IRF Quality Reporting Program2026-06-05
- Federal Register Final Rule: Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2024 and Updates to the IRF Quality Reporting Program2026-06-05
- Federal Register Proposed Rule: Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2024 and Updates to the IRF Quality Reporting Program2026-06-05
- Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2027 and Updates to the IRF Quality Reporting Program2026-06-02
OIG Fraud Alert5
- Federal Register Notice: Notice of Public Data Asset Release Under the Open, Public, Electronic, and Necessary (OPEN) Government Data Act2026-06-05
- Federal Register Proposed Rule: Request for Information (RFI) Related to Comprehensive Regulations To Uncover Suspicious Healthcare (CRUSH)2026-06-05
- Special Fraud Alert: Suspect Payments in Marketing Arrangements Related to Medicare Advantage and Providers2026-06-05
- Fraud Alerts2026-06-05
- Fraud Alerts2026-06-02
Psychiatry5
- Federal Register Proposed Rule: Medicare Program; Strengthening Oversight of Accrediting Organizations (AOs) and Preventing AO Conflict of Interest, and Related Provisions2026-06-05
- LCD L34616: Psychiatry and Psychology Services — WPS2026-06-05
- LCD L34183: Psychiatric Inpatient Hospitalization — CGS2026-06-05
- LCD L34196: Psychiatric Partial Hospitalization Programs — CGS2026-06-05
- LCD L34539: Psychological Services Coverage under the Incident to Provision for Physicians and Non-physicians — CGS2026-06-05
ICD-10 Code Update4
- AHA Coding Clinic2026-06-02
- Data & Insights2026-06-02
- ICD-10 Files2026-06-02
- ICD-10 Resources2026-06-02
Vascular4
- LCD L34536: Treatment of Varicose Veins of the Lower Extremities — WPS2026-06-05
- LCD L34082: Varicose Veins of the Lower Extremity, Treatment of — CGS2026-06-05
- LCD L34010: Treatment of Varicose Veins of the Lower Extremities — Noridian2026-06-05
- LCD L33667: Duplex Scan Of Lower Extremity Arteries — First Coast2026-06-05
Transplantation3
Nephrology2
OIG Compliance2
- News Release2026-06-05
- Special Advisory Bulletin and Other Guidance2026-06-05
Otolaryngology2
Ambulance1
- 2026 Ambulance Fee Schedule2026-06-02
Genetic Testing1
Sleep Medicine1
Speech Therapy1
Surgery1
Wound Care1
- LCD L34032: Debridement Services — CGS2026-06-05